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Abstract 
The cannabinoids compounds interact with cannabinoid receptors (CB1 and CB2), and can 
be divided into three categories: the phytocannabinoids, endocannabinoids and synthetic 
cannabinoids. Phytocannabinoids are present in the Cannabis plant, and the most studied 
compound is Δ9-tetrahydrocannabinol (Δ9-THC), though more than 60 natural 
cannabinoids have been described. Endocannabinoids were discovered in vivo and are 
involved in several physiological processes. Synthetic cannabinoids are molecules 
synthesized in laboratory with cannabimimmetic effects, primarily used for research 
purposes, but also as abuse drugs. Nowadays, the consumption of cannabis has 
increased worldwide, particularly between young adults, even though its possession and 
use is prohibited. These prohibitions lead to the emergence and increase in abuse of 
synthetic cannabinoids, known as “legal highs”, due to lack of legislation. Besides the fact 
that these substances have higher affinity to cannabinoid receptors than Δ9-THC, not 
much is known about them. A successful pregnancy is the combination of a series of well-
timed events and it was already shown that a tightly controlled endocannabinoid signalling 
is necessary. So, the consumption of exogenous substances may affect negatively these 
reproductive events. In this work, it was studied the influence of synthetic cannabinoids in 
endometrial stromal cells. These cells were treated for 24 and 48 hours with the synthetic 
cannabinoids THJ-2201, JWH-122, AB-FUBINACA, UR-144, 5F-PB-22 and WIN 55,212-2 
(0.01-50 µM). Treatments with JWH-122, AB-FUBINACA, UR-144 and 5F-PB-22 caused 
an increase in mitochondrial activity, although no changes were seen in proliferation 
studies or in the ratio between mitochondrial DNA (mtDNA) and nuclear DNA (nDNA). 
Interestingly, WIN 55,212-2 caused a decrease in cell viability, which was accompanied 
by an increase in caspase -3/-7 activities, suggesting the involvement of apoptosis. 
Furthermore, WIN 55,212-2 induced changes in cell morphology, like chromatin 
condensation as observed by Giemsa and Höechst staining. The effects of these 
compounds in endometrial stromal cells function were also investigated by assessing the 
activity of matrix metalloproteinases and concentration of prostaglandin E2, although no 
significant alterations were observed. This work showed the impact that synthetic 
cannabinoids may have in the endometrium cycle and in pregnancy establishment, by 
influencing cell proliferation and/or death. With the increasing consumption of these 
substances, especially by women in fertile age, it is important to fully understand their 
impact in reproduction. 
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Resumo 
Os compostos canabinóides interagem com os recetores canabinóides (CB1 e CB2), e 
podem ser divididos em três categorias: os fitocanabinóides, endocanabinóides e 
canabinóides sintéticos. Os fitocanabinóides encontram-se na planta Cannabis, e o 
composto mais estudado é Δ9-tetra-hidrocanabinol (Δ9-THC), embora mais de 60 
canabinóides naturais tenham sido descritos. Os endocanabinóides foram descobertos in 
vivo e estão envolvidos em vários processos fisiológicos. Os canabinóides sintéticos são 
moléculas sintetizadas em laboratório com efeitos canabinomiméticos, utilizados 
principalmente na investigação, mas também como drogas de abuso. O consumo de 
canábis aumentou em todo o mundo, em particular entre os jovens, embora a sua posse 
e consumo sejam proibidos. Estas proibições levaram ao aparecimento e aumento do 
abuso de canabinóides sintéticos, conhecidos como "drogas legais" devido à falta de 
legislação. Apesar destas substâncias terem maior afinidade para os recetores 
canabinóides do que Δ9-THC, pouco se sabe sobre o modo de atuação destas moléculas. 
Uma gravidez de sucesso é a combinação de uma série de eventos altamente regulados 
e já foi demonstrado que a é necessária uma sinalização endocanabinóide rigidamente 
controlada. Assim, o consumo de substâncias exógenas pode afetar negativamente estes 
eventos reprodutivos. Neste trabalho, estudou-se a influência de canabinóides sintéticos 
em células do estroma endometrial. Estas células foram tratadas durante 24 e 48 h com 
os canabinóides sintéticos THJ-2201, JWH-122, AB-FUBINACA, UR-144, 5F-PB-22 e 
WIN 55,212-2 (0,01-50 µM). Tratamentos com JWH-122, AB-FUBINACA, UR-144 e 5F-
PB-22 induziram um aumento da atividade mitocondrial, embora não se tenham 
observado alterações na proliferação celular ou ainda na relação entre o DNA 
mitocondrial (mtDNA) e DNA nuclear (nDNA). Curiosamente, o WIN 55,212-2 causou 
uma diminuição na viabilidade celular, o que foi acompanhado por um aumento da 
atividade da caspase -3/-7. Além disso, o WIN 55,212-2 induziu condensação da 
cromatina como observado com a coloração de Giemsa e Höechst. Os efeitos destes 
compostos na função das células do estroma endometrial foram também investigados 
através da determinação da atividade de metaloproteinases e dos níveis de 
prostaglandina E2, no entanto não foram observadas alterações significativas. Este 
trabalho mostra o impacto que os canabinóides sintéticos podem ter no ciclo endometrial 
e no estabelecimento de gravidez, ao influenciar a proliferação e/ou morte das células do 
estroma uterino. Com o aumento do consumo destas substâncias, especialmente por 
mulheres em idade fértil, é crucial compreender o impacto destas drogas na reprodução. 
 
Palavras-Chave: canabinóides, canabinóides sintéticos, endométrio, gravidez  
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1. Cannabinoids 
 
1.1 Historical Background 
 
The cultivation of the Cannabis plant with medicinal purposes was originally 
described in ancient China, where it was considered effective treating pain (1, 2). 
However, in the 19th century, the research of the chemistry and pharmacology of 
Cannabis constituents increased, culminating in 1964 with the discovery of its major 
psychoactive component, the Δ9-tetrahydrocannabinol (Δ9-THC) (3, 4). 
Cannabis is a flowering plant with three species: sativa, indica and ruderalis, with 
the plants being assorted according to the levels of Δ9-THC they contain. It is easily 
cultivated outdoors in most parts of the world and anywhere indoors under proper 
conditions. From a Cannabis seedling, distinct products can be obtained: herbal Cannabis 
(marijuana) and Cannabis resin (hashish). The psychoactive effects can cause changes in 
memory, perception, psychomotor activity and consciousness, which are probably the 
reasons why Cannabis is still one of the most popular recreational drugs in Western 
societies, even though its use is forbidden in some countries (2, 5-7). 
Cannabinoids were, until recently, characterized as terpenophenolic constituents 
of Cannabis sativa plant. Currently, cannabinoids can be divided in three types: the plant-
derived natural products, the “phytocannabinoids”; the synthetic cannabinoids; and the 
animal-derived, the “endocannabinoids” (8, 9). Thus, cannabinoids include all the 
molecules that activate cannabinoid receptors (9, 10). 
 
1.2 Cannabinoid Receptors 
 
The discovery of Δ9-THC increased the study of cannabinoid pharmacology, which 
culminated in the discovery of cannabinoid receptors (CBR). The first cannabinoid 
receptor to be described was the cannabinoid receptor type 1 (CB1), which was cloned 
after screening of previously characterized orphan G-protein-coupled receptors (GPCRs) 
for their affinity for Δ9-THC, followed by a second one, the cannabinoid receptor 2 (CB2) 
identified by homology cloning (11-13). 
The CB1 and CB2 are transmembrane receptors coupled to protein G and present 
different sequences of amino acids and tissue distribution. The CB1 seems to be mainly 
expressed in the brain, although it can be found in peripheral tissues such as the 
placenta, fetal membranes, myometrium (uterus) and testes (1, 11, 14, 15). The CB2 
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receptor is primarily expressed by the immune system cells, even though it is expressed 
in the central nervous system and also in peripheral tissues (12, 16-18). 
The cannabinoid receptor binding may cause the activation of different signalling 
pathways (11, 12, 19, 20). Compounds with high binding affinity for cannabinoid receptors 
are considered direct ligands that can act as agonist or inverse agonist. Indirect ligands 
can exert their effects by targeting key proteins that regulate tissue levels of 
endocannabinoids or allosteric sites of CB1 (9).   
 
1.3 Endocannabinoids 
 
Endocannabinoids were discovered in vivo after the identification of Δ9-THC. The 
two endocannabinoids whose biological activity has been better characterized are N-
arachidonoylethanolamine (anandamide; AEA) and 2-arachidonoylglycerol (2-AG) (21). 
Both chemical structures are represented in Figure 1. Like Δ9-THC, AEA and 2-AG, bind 
to the extracellular site of the CB1 and CB2 (11, 12, 22, 23). Despite these two well-studied 
endocannabinoids, there are also the 2-arachidonyl-glycerol ether (noladin-ether) (24), the 
N-arachidonoyl-dopamine (NADA) (25, 26) and virodhamine (27), whose metabolism and 
pharmacological activity are yet to be fully investigated (13). More recently, it was 
identified the first potent endogenous antagonist of CB1, a nonapeptide known as 
hemopressin, found in numerous tissues including the brain, but more studies of its 
metabolism and regulatory levels are needed (13).  
AEA, an endogenous eicosanoid derivative, is released by the cleavage of the 
phospholipid precursor N-acyl phosphatidylethanolamine (NAPE). The synthesis of this 
precursor is catalysed by the N-acyltransferase (NAT), whereas a specific phospholipase 
D, the N-acylphosphatidylethanolamine-specific phospholipase D (NAPE-PLD) is 
responsible by the release of AEA from NAPE. 
 
 
 
 
 
 
 
 
 
Figure 1 – The chemical structures of the major endocannabinoids. AEA and 2-AG have different 
biosynthetic pathways, although both are produced on demand by cleavage of membrane phospholipds 
precursors.   
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2-AG is produced by the cleavage of a membrane phospholipid, by 
phosphatidylinositol (PI) and, sometimes, from the hydrolysis of phosphatidic acid (28) to 
produce 1,2-diacylglycerol (DAG). The formation of this compound is catalysed by 
phospholipase C (PLC), that after conversion via a membrane-bound diacylglycerol lipase 
(DAGL), gives rise to 2-AG.  
These endocannabinoids are suppressed by enzymatic hydrolysis of their amide 
and ester bonds by a membrane fatty acid amide hydrolase (FAAH) and/or by a 
membrane-associated serine hydrolase, monoacylglycerol lipase (MAGL) (29-31). The 
AEA hydrolysis is mainly mediated by FAAH to generate ethanolamine (EtNH2) and 
arachidonic acid (AA), whereas 2-AG is degraded to AA and glycerol by MAGL or also by 
FAAH, though the former is considered the main degrading enzyme. 
AEA binds to both cannabinoid receptors and, like Δ9-THC, it has lower efficacy 
and affinity for CB2 than for CB1. AEA can also activate other receptors, such as the 
orphan G protein-couple receptor 55 (GPR55), the transient receptor potential vanilloid 1 
(TRPV1) and the peroxisome proliferator-activated receptor-γ (PPAR-γ) (2, 32-34). 2-AG 
affinity and efficacy to CB1 and CB2 is higher than AEA and it can also interact with PPAR-
γ, but not with TRPV1 or GPR55 (21, 35). 
The AEA and 2-AG pharmacological effects depend on their concentration in the 
extracellular space, which is limited by the transport through the cell membrane, either by 
passive diffusion or by endocannabinoid membrane transporter (EMT) (22, 36). The 
endocannabinoids, together with the respective metabolic enzymes and cannabinoid 
receptors constitutes the endocannabinoids system, a lipid signalling network in which 
different proteins can control or modulate various physiological and pathophysiological 
processes (9, 37, 38). The endocannabinoid system elements are represented in Figure 
2.  
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Figure 2 – The components of the endocannabinoids system. The biosynthesis of AEA (blue circles), is 
catalysed by NAT followed by NAPE-PLD, and the biosynthesis of 2-AG (orange circles) occurs through 
DAGL. Endocannabinoids are transported in both directions through cell membrane by diffusion or selective 
transport via the EMT. In the extracellular space can interact with CBR or be internalized and degraded. AEA 
is hydrolyzed by FAAH into EtNH2 and AA. 2-AG is hydrolyzed through MAGL or FAAH into glycerol and AA. 
Adapted from (21). 
 
1.4 Phytocannabinoids 
 
Plant derived natural products that are able to directly interact with cannabinoid 
receptors or share chemical similarities with cannabinoids, or both, are known as 
phytocannabinoids (9).  
There are more than 60 naturally occurring substances found in Cannabis sativa 
such as Δ9-THC, cannabidiol (CBD), cannabinol (CBN) and cannabigerol (CBG) (Figure 
3). Besides its psychoactive properties, Δ9-THC also presents muscle relaxant, analgesic 
and antispasmodic characteristics. CBD is a nonpsychotropic constituent of Cannabis, 
being a versatile pharmacological agent, causing some of the effects of Δ9-THC, such as 
sedation, and it has the ability to act as an antagonist of CB1, evidenced by reducing Δ
9-
THC psychomimetic effects. CBN, like CBD, has a low affinity for the cannabinoid 
receptors and causes sedation when combined with Δ9-THC (9, 39-41).  
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Figure 3 – The chemical structures of the main phytocannabinoids. The psychoactive component, Δ
9
-
THC, and other natural substances found in Cannabis plant, such as CBD, CBN and CBG. 
 
1.5 Synthetic cannabinoids 
 
Synthetic cannabinoids began being developed in the 1960s after the discovery of 
Δ9-THC, to help investigate the endocannabinoid system pharmacology and its potential 
therapeutic effects, emphasizing in the analgesic and anti-inflammatory properties and 
eliminating the psychoactive effects. The majority of these new synthetic cannabinoids 
were synthesized in four laboratories: John W. Huffman, Alexandros Makriyannis, Pfizer 
and Hebrew University, and now are known by their initials (JWH, AM, CP and HU) (42-
45). 
The structure of the major synthetic cannabinoids can be divided into four parts: 
the core and substituents, the link section, the ring and substituents and the tail section 
(46) (Figure 4).  
 
 
 
 
 
 
 
Figure 4 – The general chemical structure of the main synthetic cannabinoids. The majority of synthetic 
cannabinoids follow this general structure. From (46). 
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These new substances can be classified by their chemical structure, as suggested 
by Howlett et al. and Thakur et al. (16, 47) and the Advisory Council on the Misuse of 
Drugs and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (48, 
49) divides synthetic cannabinoids into seven groups: naphtoylindoles, 
naphtylmethylindoles, naphtoylpyrroles, naphtylmethylindenes, phenylacetylindoles, 
cyclohexylphenols and classical cannabinoids (Table 1). 
 
Table 1 – Classification of synthetic cannabinoids.  The generic definition of the seven major groups of 
synthetic cannabinoids and respective examples. 
 
Cannabinoids Generic definition Example Reference 
Naphtoylindoles and 
Naphtylmethylindoles 
Any compound structurally derived from 3-(1-
naphthoyl)indole or 1H-indol-3- yl-(1-
naphthyl)methane by substitution of the indole 
ring 
JWH-018 (Figure 
5A); JWH-185 
(Figure 5B) 
(48, 49) 
Naphtoylpyrroles 
Any compound structurally derived from 3-(1-
naphthoyl)pyrrole by substitution of the pyrrole 
ring 
JWH-369 (Figure 5C) 
Naphtylmethylindenes 
Any compound structurally derived from 1-(1-
naphthylmethyl)indene by substitution of the 
indene ring 
JWH-176 (Figure 5D) 
Phenylacetylindoles Any compound structurally derived from 3-
phenylacetylindole by substitution of the indole 
JWH-250 (Figure 5E) 
Cyclohexylphenols 
Any compound structurally derived from 2-(3-
hydroxycyclohexyl)phenol by substitution of the 
phenolic ring 
CP 47,497 (Figure 
5F) 
Classical Cannabinoids Any compound structurally related to Δ
9
-THC 
and other constituents of cannabis 
HU-210 
(Figure 5G) 
 
These new substances have psychoactive effects as Δ9-THC. Also the chemical 
properties are similar, sharing with Δ9-THC high lipophilicity. Nonetheless, though the 
ability to bind to the cannabinoid receptors is higher, these are not structurally similar to 
classic cannabinoids (48). In fact, some of these synthetic cannabinoids have even higher 
affinity to the receptors than Δ9-THC due to their full agonist capability and active 
metabolites. In addition, the possibility that they may also interact with other receptors 
could explain why they are more potent than Δ9-THC (40, 50-52). This can cause a variety 
of symptoms that can go from mild to moderate, like nausea, emesis and agitation to more 
severe such as cardiac arrhythmias, psychosis, respiratory depression to coma and even 
death (51, 53, 54). 
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Figure 5 – The chemical structures of synthetic cannabinoids. Examples of each one of the seven major 
classes of synthetic cannabinoids. A – Naphtoylindoles; B – Naphtylmethylindoles; C – Naphtoylpyrroles; D – 
Naphtylmethylindenes; E – Phenylacetylindoles; F – Cyclohexylphenols; G - Classical Cannabinoids. 
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1.6 Cannabinoids and drug abuse 
 
Cannabis use, in such different forms, is prevalent in every European Union (EU), 
with an upward trend in young adults, as seen in Figure 6. A recent analysis made by the 
EMCDDA revealed that over a quarter of 15- to 64-years olds in EU is thought to have 
consumed the drug at least once in their lifetime. On the other hand, the use amongst 
young individuals (15-34 years) within the last 12 months is about 13,3 % or 16.6 million 
EU individuals, which makes Cannabis derivatives the most widely consumed illicit drug 
by both adults and youths in the world (55).  
 
 
 
Figure 6 – Cannabis use in Europe by young adults (15-34). In the left, the countries with significant 
statistically trends in Cannabis use are represented and, in the right is the most recent data (2015) about 
Cannabis use in Europe. It was observed an increase in consumption in France, Italy, Finland, Czech 
Republic and Sweden, but with different prevalence. However, Spain, Germany and the United Kingdom 
showed a decrease in Cannabis use in the last decade. Bulgaria, with less data available, has upward trends. 
From (55). 
 
In the last decade the availability of new psychoactive substances (NPS) has 
increased in the European market (Figure 7). These new drugs, natural or synthetic, are 
produced to mimic effects of controlled substances and are known as “legal highs”. On the 
other hand, the rapid modification of chemicals, the unknown quantity of drug used and 
the unknown herbal components that are difficult to detect in a typical drug screen, and 
the lack of reference samples to make detection possible, makes these new synthetic 
cannabinoids potentially dangerous to human health (51, 52).  
The majority of these new substances are sold as alternatives to cannabis, heroin, 
cocaine, amphetamines, 3,4-methylenedioxy-methamphetamine (MDMA), 
benzodiazepines and lysergic acid diethylamide (LSD), and can be found in either the 
Internet as in specialized shops – head shops – being advertised as “research chemicals”, 
“food supplements” or as “not intended for human consumption” (56). 
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Synthetic cannabinoids is the largest group of NPS with more than 160 different 
synthetic cannabinoids identified till December 2015. Usually, these substances are 
produced in China or India and arrive in Europe where they are sold as chemical powders 
or herbal mixtures similar to potpourri or incense that can be smoked, and also used as 
infusions or even in e-cigarettes. The common street names of the new drugs are: Spice, 
K2, Bhang, Yucatan and Mojo. These are not marijuana, but really a combination of 
various synthetic compounds that can interact with the cannabinoid receptors and induce 
marijuana-like effects (46, 51, 52, 56).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 – New psychoactive substances notified to the EU Early Warning System. Number and 
categories of new psychoactive substance reported to the Eu Early Warning System increased 25% compared 
to 2013, including 30 new synthetic cannabinoids. From (57).    
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2. Cannabinoids and signalling pathways 
 
Cannabinoids exert their effects by binding to specific cannabinoid receptors, 
usually activated by the endogenous ligands, the endocannabinoids. These receptors are 
able to regulate several central nervous system functions, such as neuronal development, 
neuromodulatory processes and several peripheral physiological functions, for instance 
cardiovascular, respiratory, digestive and reproductive systems. Additionally, they can 
also modulate proliferation, motility, adhesion and apoptosis of cells (58, 59).  
Both cannabinoid receptors belong to the GPCR superfamily, and more specific, 
the rhodopsin subfamily of GPCRs, and are characterized by 7-transmembrane domains, 
an extracellular NH2 terminus and an intracellular COOH terminus (18). They are also 
associated with G proteins of the Gi/o family (Gi 1, 2 and 3; Go 1 and 2) (11, 12). The 
activation of cannabinoid receptors leads to inhibition of the adenylyl cyclase (AC) 
enzyme, activation of mitogen-activated protein kinases (MAPKs) and modulation of ion 
channels, in this case only through activation of CB1, as represented in Figure 8. 
 
 
Figure 8 – Cannabinoid signalling pathways after activation of the cannabinoid receptors coupled to G 
protein. This leads to inhibition of adenylyl cyclase, inducing a decrease in cAMP levels, which translates in a 
decrease of PKA. The activation also activates MAPKs, such as PKB, and induces an increase in ceramide 
levels, through sphingomyelin hydrolysis by SMase, which regulates ERK, p38 MAPK and JNK. Additionally, 
CB1 can negatively couple to N- and P/Q-type voltage-operated Ca
2+
 channels and induce an increase in 
intracellular Ca
2+
.  
 
Even before cannabinoid receptors were described, it was already known that 
cannabinoids caused inhibition of the AC, which leads to a reduction of intracellular cyclic 
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AMP (cAMP) levels. cAMP is responsible for numerous roles inside the cell, such as the 
phosphorylation of proteins through protein kinase A (PKA). Essentially, decreased cAMP 
in cells that express CB1 and CB2 will most likely culminate in an inhibition of function of 
those cells (59, 60). 
Both cannabinoid receptors are also able to regulate the phosphorylation and 
activation of the family of mitogen-activated protein kinase (MAPK). Activation of 
extracellular signal-regulated kinase-1 and -2 (ERK1/2), also known as p42/p44 MAPK, by 
CB1 receptors, requires mobilization of the phosphatidylinositol-3-kinase (PI3K) and 
protein kinase B (PKB/Akt) which results in the phosphorylation of Raf-1. p38 MAPK and 
c-Jun N-terminal kinase (JNK) can also be regulated by these receptors (58, 59, 61). 
The sphingolipid-metabolising pathways also seem to be modulated by 
cannabinoids. Neutral sphingomyelinase activation (FAN) is the possible adaptor protein 
responsible for the hydrolysis of sphingomyelin (SM) via sphingomyelinase (SMase) 
activation. This activation can cause a peak of ceramide accumulation by enhanced 
synthesis de novo via serine palmitoyltransferase (SPT), which is important in the 
regulation of metabolic functions, such as induction of apoptosis, via a ERK/p38/JNK (59, 
62). 
The activation of cannabinoid receptors is also responsible for the regulation of 
other key proteins, including the focal adhesion kinase that plays a part in synaptic 
plasticity (63); activation of phospholipase A2, via MAPK, inducing the arachidonic acid 
cascade and production of prostaglandins (64); is also able to decrease the synthesis of 
growth factor receptors in some tissues, what could explain the antiproliferative effects of 
cannabinoids (65). 
However, cannabinoid receptors agonists have different affinities to agonists and 
the activated signalling pathways can differ from cell to cell, which may account to the 
various cells responses obtained upon binding to receptors (60). CB1, additionally, can 
negatively couple to N- and P/Q-type voltage-operated Ca2+ channels and positively 
couple to A-type and inwardly rectifying K+ channels, and through G protein-dependent 
activation of phospholipase C-β (PLC-β) induce an increase in intracellular Ca2+ (58).    
The involvement of different mitogen- and stress- activated protein kinase 
cascades in the control of cell fate, and the evidences that cannabinoid receptors interact 
with these signalling pathways, show that cannabinoids may play an important role in the 
cell survival/death decision (59).  
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3. Cannabinoids and Pregnancy 
 
3.1 The endometrium and menstrual cycle 
 
 The endometrium is composed of epithelial and mesenchymal elements that suffer 
different morphological alterations during the menstrual cycle. The superficial epithelium is 
formed of epithelial cells, and the mesenchyme, or stroma, contains predominantly 
fibroblasts. It can also be divided into two different layers based on morphological and 
physiological characteristics, such as, the basalis, the deepest layer with a constant 
morphology during the menstrual cycle, and the functionalis, the superficial layer, where 
most of the alterations occur to allow the blastocyst implantation (66). 
 The two primary steroid hormones are estrogen (E2) and progesterone (P4), which 
are mainly produced in ovaries and are responsible for the cyclic changes in morphology 
and function during the menstrual cycle. Due to fluctuations of these hormones, menstrual 
cycle can be divided into three phases: in the proliferative phase, the levels of estrogen 
increase, inducing the thickening of the functionalis layer, by proliferation of epithelial, 
stromal and endothelial cells; in the secretory phase, which occurs after ovulation, the 
differentiation of the functional layer starts, due to the influence of progesterone, produced 
by the corpus luteum. It is at the end of this phase that decidualization begins. When no 
implantation occurs, the levels of estrogen and progesterone decrease, due to the decay 
of the corpus luteum, leading to shedding of the functional layer and consequent 
menstrual bleeding, which characterises the menstrual phase (Figure 9) (66, 67).     
  Studies suggest that menstrual bleeding is a secondary effect of extracellular 
matrix (ECM) proteolysis (68) and, although numerous proteinases and enzymes 
expressed in human endometrium seem to participate in menstruation, the most important 
enzymes for direct ECM proteolysis is the matrix metalloproteinases (MMP) family. MMP 
are Zn-dependent proteinases capable of degrading the ECM and regulate several 
signalling molecules like cytokines and chemokines. The endometrium has plenty of MMP 
transcripts and proteins, particularly during menstruation, and of all MMP studied only 
MMP-13 was not detected in the human endometrium. The major regulator of MMP 
expression is progesterone (66).         
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Figure 9 – The menstrual cycle in humans. The 28- to 30 days menstrual cycle begins with menstruation, 
followed by the proliferative phase (red), which is under the influence of increasing estrogen levels, produce 
by growing ovarian follicles, which induce the proliferation of the endometrium. By midcycle, a surge of 
gonadotropins (LH and FSH) occur, leading to ovulation on day 14 (green). In the luteal phase, the thickening 
of the endometrium, formation of the corpus luteum and subsequent secretion of progesterone is the 
preparation for implantation of the blastocyst. Decidualization starts and the estrogen levels increasing 
overlapping on progesterone define the “implantation window”. In the absence of pregnancy, the window 
progresses to a refractory phase, leading to luteolysis, hormone withdrawal and menstruation (69). 
 
3.2 The endometrium and pregnancy establishment  
 
A successful pregnancy, which is the nurturing of the offspring within the womb 
and the production of a live birth, depends on a sequence of well-timed events since 
fertilization to parturition. It all starts with the fertilization of an egg by a spermatozoid, the 
zygote, in the Fallopian tube. Then, it travels through the oviduct, suffering multiple 
divisions and developing into a blastocyst, until it reaches the uterus, where it will adhere 
to the decidualized endometrium. This sequence of events starts with proper 
establishment of a receptive endometrium and a competent blastocyst (67). 
Implantation is an intrusive process and occurs during the mid-secretory phase, in 
a 2- to 4 day period called “implantation window”, during which the endometrium is 
prepared by estrogen and progesterone. It can be divided into three stages: apposition, 
adhesion and invasion. During apposition, the first contact between blastocyst and 
endometrium is made and the location for implantation is found. The invasion of the 
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endometrium by the blastocyst is when the trophoblast cells infiltrate the endometrial 
epithelium and into the endometrial stroma until reaching blood vessels (67, 70). 
The uterine endometrium is prepared every month for the possible implantation of 
a blastocyst and this process is known as decidualization. The rapid proliferation of 
epithelial and endometrial stromal cells is followed by the differentiation of the glandular 
epithelium into a highly secretory state. Ultimately, the fibroblast stromal cells differentiate 
into enlarged and glycogenic rich cells with a polygonal morphology, which characterises 
the decidual cells (71, 72). It also involves a tightly regulated expression of specific 
adhesion molecules, growth factors and cytokines (72, 73). 
Decidua can be classified into three types relative to the developing conceptus: the 
decidua basalis, the region beneath the site of implantation; decidua capsularis, the region 
over the developing conceptus, and the remaining is the decidua vera or decidua 
parietalis (67). Decidua is mostly comprised of decidualized endometrial stromal cells, but 
it also has other cell types, like hematopoietic cells, macrophages, uterine natural killers 
and monocytes, associated with blood vessels, and uterine glands (74). To promote the 
adhesion of the trophoblast cells, the decidua forms a dense cellular matrix that, at the 
same time, helps to limit the aggressive invasion of those cells. This invasion depends 
upon proteolytic degradation and remodelling of the decidual extracellular matrix, which is 
accomplish by the MMPs secreted by the trophoblast cells, and by decidualized stromal 
cells, as shown by recent studies (75). Thus, decidualization results in these cells 
acquiring biochemical and cellular properties that facilitates them support implantation 
(67).       
If the decidual process does not occur normally, pregnancy complications may 
happen, such as miscarriage, preeclampsia, foetal growth restriction and preterm labour 
(76). Although it was already shown that implantation and even successful pregnancies 
can occur without the decidua (77, 78), it is the successful decidualization that is important 
for implantation and success of normal pregnancies (73).   
On the other hand, development and function of the placenta is the key to an 
adequate exchange of nutrients and gas between mother and foetus, which is intimately 
dependent on endometrial environment.  
 
3.3 Endocannabinoids and pregnancy 
 
It was already described that endocannabinoid system is implicated in several 
physiological and pathological processes, such as the reproductive system (79). 
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Evidences of their role in decidualization, embryo development and implantation were 
already shown (80).  
AEA, 2-AG and respective metabolic enzymes were found in the mouse 
endometrium and their concentration varies during the oestrus cycle (81). In humans AEA 
levels increase in the menstrual cycle at the time of ovulation, the cannabinoid receptors 
are present in the ovaries, and NAPE-PLD is expressed by granulosa and theca cells, 
meaning that AEA is more likely to be produced by granulosa of growing cells than by 
oocytes. In addition, considering that follicular AEA concentrations are related to follicular 
size and that are lower in follicles from which  oocytes were retrieved, it is suggested that 
AEA is involved in the maturation of follicles and oocytes (82-84). 
Additionally, mouse embryos express cannabinoid receptors and high doses of 
AEA can induce a dose-dependent suspension of embryo development, and even 
inhibition of blastocyst hatching (85). Mouse embryos with cannabinoid receptor 
abnormalities also present delayed development (86). Furthermore, it was shown in mice 
that CB1 is important to assure embryo transport through the oviduct as CB1 knockout 
mice showed high levels of abortion (87).    
AEA levels are higher in the endometrium than in other reproductive tissues (88, 
89). Both cannabinoid receptors, NAPE-PLD and FAAH proteins were also detected in 
decidua from pregnant women (76). The presence of cannabinoid receptors, 
endocannabinoids and respective metabolic enzymes in the female reproductive system, 
with evidences of their presence in maternal and foetal tissues suggests that these are 
involved in decidualization of the endometrium, oviduct transport and implantation of the 
embryo (76).  
 
3.4 Cannabinoids use by pregnant women 
 
Cannabis is the most consumed illegal substance by pregnant women in Western 
societies, with nearly 3 % of reported cases by pregnant women in the United States 
(Figure 10). The lipophilic characteristics of cannabinoids, allows them to cross cell 
barriers, including transplacental membranes (90). This explains the presence of 
Cannabis metabolites in many human tissues (91), such as the placenta, amniotic fluid 
and foetus (92), making the study of its effects on reproduction important (7). 
Most studies show that continuous use of Cannabis is associated with reduced 
fertility and failed pregnancies. It is also shown that Cannabis is correlated with congenital 
foetal abnormalities and intrauterine growth restriction (93-95), leading to the general 
conclusion that maternal use of Cannabis during pregnancy affects birth outcome and 
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foetal development. However, contradictory results have also been published, as some 
studies show that infants exposed to Cannabis during pre-natal life did not show 
increased risks of birth defects (95-97). 
The studies to discover the full extent of Cannabis use during pregnancy are few 
due to ethics problems that forbid the experiments in human tissues. In addition, the small 
number of studies that were published are controversial, due to the fact that women that 
use Cannabis frequently also consume other drugs and have adverse lifestyles (98, 99).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 – Illicit drug use in the United States of America by pregnant women. Approximately 4% of 
women admitted the use of illicit drugs while pregnant, with Cannabis as the most commonly used drug. Data 
from 2005. Adapted from (100). 
 
The human studies published to date consist in following pregnant women that 
admitted the usage of substances that may affect the pregnancy outcome. In most of 
these studies the parameters that were examined were the ones related to foetal growth. 
In a study with 1690 children, the birth weight was lower for foetus exposed more than 
three times per week to Cannabis (95). In other study the increased risks of low birth 
weight was two times higher in foetus exposed several times a month to Cannabis (101).  
One of these studies was the Generation R, that started in 2002 and consisted in 
assessing the foetal growth in early, mid and late pregnancy using techniques such as 
femur length, abdominal and head circumference and transcerebellar diameter (102, 103). 
In the Generation R study, 8880 pregnant women were enrolled and the results showed 
that foetal growth, especially birth weight, was reduced in mothers that used Cannabis in 
early pregnancy comparing to tobacco users and non-users. In mothers that used 
Cannabis continuously during pregnancy, the birth weight was even lower comparing to 
only early usage. The head circumference of foetuses was also reduced in early and 
continuous use during pregnancy compared to non-exposed foetuses. However, the 
transcerebellar diameter did not show any differences (103). 
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In Cannabis-exposed pregnant women, the use of Doppler showed an increased 
foetal pulsatility and resistance index of the uterine artery, which could explain the growing 
deficit in exposed foetuses (104, 105). Other studies also observed influence on the 
preterm birth rate, which increased with Cannabis use (106).  
Studies have already shown that Δ9-THC can cross the placenta in animals and 
humans (107) and that the behaviour of Δ9-THC concentrations in the foetus are similar to 
the maternal. However, the concentrations in foetal blood were lower than in maternal 
blood in several species. The ways of intake can affect the concentrations reached in 
blood. In oral intake the foetal concentrations can be one-tenth of the maternal (108) 
comparing to the one-third if the intake occurs by intravenous or inhaled Δ9-THC (109, 
110). Involving dizygotic twins, the importance of the placenta in the variability of foetal 
exposure to Δ9-THC was determined, in which large disparities were found regarding 
cannabinoid concentrations with undetectable levels in one twin and high levels in the 
other (40, 111). 
The influence of the cannabinoid receptors in the placenta was also a subject of 
study and it was found that the CB1 receptor is present in all of the placental layers and 
that the stimulation of this receptor is responsible for the impaired foetal growth (7, 14, 
112). Costa et al. studied the in vitro effects of Δ9-THC using human trophoblasts 
(placental epithelial cells) from term placenta (113). The results showed that Δ9-THC 
impaired the differentiation of cytotrophoblasts into syncytrophoblasts, and in low 
concentrations demonstrated to be cytoprotective, preventing cell death. Both of these 
findings occurred through a cannabinoid receptor-dependent mechanism. So, Δ9-THC 
inhibits trophoblast turnover, impairing placental development by disturbing key 
processes, such as proliferation, differentiation and apoptosis of cytotrophoblasts (113).   
 
Table 2 - Retrospective studies on Cannabis use by pregnant women. Published studies analysing the 
impact of Δ
9
-THC in pregnancy. 
 
Cannabinoid Effects observed Reference 
Δ
9
-THC 
Decreased birth weight (101) 
Decreased birth weight (95) 
Decreased foetal growth 
Decreased head circumference 
(103) 
Increased preterm birth rate (106) 
 
The effects of synthetic cannabinoids in human reproduction are yet to be fully 
unveiled, but considering that Cannabis use among pregnant women seems to cause 
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adverse effects in placental development and foetal growth (113) and the fact that 
synthetic cannabinoids bind to cannabinoids receptors with higher affinity and potency 
should be of concern (2). It is also important to acknowledge that most of the users of 
synthetic cannabinoids use others synthetic drugs, such as synthetic cathinones, also 
known as bath salts (114).          
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The endocannabinoid system is a signalling network that can regulate several 
physiological processes, including reproduction. Cannabinoid receptors expression in the 
placenta, foetal membranes and endometrium, along with the endocannabinoids ability to 
regulate different signalling pathways involved in cell survival and their role in 
decidualization, embryo development and implantation shows that a tightly controlled 
endocannabinoid signalling is necessary for a successful pregnancy.  
The emergence and increasing use of new psychoactive substances, like synthetic 
cannabinoids, which share similar psychoactive effects with Δ9-THC with higher affinity for 
the cannabinoids receptors and possible interaction with endocannabinoid system, 
present a new matter of concern. Furthermore, lack of the pharmacological information 
about the synthetic cannabinoids translated in a variety of symptoms, besides the 
psychoactive effects, can be quite harmful.  
It was already observed that the consumption of Cannabis before and during 
pregnancy affect fertility, birth outcome and foetal growth. These findings together with the 
higher affinity to cannabinoid receptors of synthetic cannabinoids and increased abuse of 
these new substances during fertile age may represent a risk for fertility and for the 
normal progression of a future pregnancy.  
Therefore, with this study we pretend to investigate the influence of different 
synthetic cannabinoids in endometrial stromal cells, using a cell line model, St-T1b, and 
primary cultures of human decidual fibroblasts, HdF, hoping to contribute to the 
understanding of the effects of cannabinoids abuse in endometrium development.  
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1.1 Materials  
 
Dulbecco’s Modified Eagle Medium/F12 (DMEM/F12), foetal bovine serum (FBS), 
antibiotic–antimycotic solution (penicillin G sodium, streptomycin sulphate and 
amphotericin B) and trypsin were from Gibco/Invitrogen Corporation, Carlsbad, CA, USA. 
Trypan blue, activated charcoal, Triton X-100, methylthiazolyldiphenyl-tetrazolium bromide 
(MTT), Höechst 33342, 16S and GAPDH primers, Sulforhodamine B sodium salt, gelatin 
form porcine skin and BrdU antibodies were from Sigma–Aldrich Co. St. Louis, MO, USA. 
Ethanol and methanol were from Fisher Scientific, Loughborough, UK. DMSO was from 
VWR, Fontenay-sous-Bois, France. WIN 55,212-2, AM251 and AM630 were from Tocris 
Bioscience, Bristol, UK. AM281 and broad range molecular markers were from Santa 
Cruz Biotechnology, CA, USA. Δ9-THC was from Lipomed AG, Swiss. CytoTox 96 Non-
Radioactive Cytotoxicity Assay Kit and Caspase-Glo 3/7 were from Promega. Giemsa was 
from Merck. Bradford assay reagent was from Bio-Rad, Laboratories Melville, NY, USA. 
TRIsure was from Bioline Reagents Ltd., UK. Prostagladin E2-d4 was from Cayman 
Chemical Company. BrdU was from Boenhringer Mannheim, Germany. THJ-2201, JWH-
122, AB-FUBINACA, UR-144 and 5F-PB-22 (Figure 11) were provided from the 
Laboratory of Toxicology from the Faculty of Pharmacy of University of Porto, Portugal. 
Ninety-six-well white plates were from Thermo Scientific, Roskilde, Denmark.  
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Figure 11 – Chemical structures of the synthetic cannabinoids used in this work. These synthetic 
cannabinoids have different affinities to CB1 and CB2. WIN 55,212-2: CB1 (1.9 nM); THJ-2201: CB1 (1.0 nM) 
and CB2 (2.6 nM); JWH-122: CB1 (0.69 nM) and CB2 (1.2 nM); AB-FUBINACA: CB1 (0.9 nM) and CB2 (23.2 
nM); UR-144: CB1 (150 nM) and CB2 (1.8 nM); 5F-PB-22: unknown. 
 
 
1.2 Cell cultures  
 
1.2.1 St-T1b cell line 
 
St-T1b is a telomerase-immortalized human endometrial stromal cell line, well-
accepted as an endometrial cell model, kindly provided by Dr Birgit Gellersen from 
Endokrinologikum Hamburg (Centre for Endocrine, Metabolic and Fertility Disorders), 
Germany. 
St-T1b cells were maintained in culture in DMEM/F12 medium supplemented with 
10 % (v/v) of FBS treated with activated charcoal (FBS-CT), 1 % (v/v) of an antibiotic-
antimycotic (AB-AM) solution, 1 nM 17-β-estradiol and 1 μg/ml Insulin and were incubated 
at 37 °C in 95% air/5% CO2 humidified atmosphere. After reaching about 80% of 
confluence, cells were successively sub-cultured to new culture flasks. For this, cells were 
treated with 0.25 % trypsin/EDTA 1 mM for 4 min at 37 ºC, washed with PBS and 
collected to centrifuge tubes with culture medium containing 10 % FBS-CT (v/v) to 
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inactivate trypsin. Cells were centrifuged at 180 xg for 5 min at 4 ºC. Then cells were 
counted in a Neubauer chamber and cultured using the cell densities: 0,5x104 cells/well 
(final volume 200 μL) for 96-well plate, 2,5x104 cells/well (final volume 500 μL) for the 24-
well plate and 5x104 (final volume 2000 μL) for the 6-well plate. After adherence (24 
hours), the cells were washed with PBS and treated with the compounds, in cell culture 
medium with 2 % (v/v) FBS-CT.  
 
1.2.2 Isolation and primary cultures of human 
decidual fibroblasts  (HdF) 
 
Term placentas from caesarean section or vaginal delivery, following 
uncomplicated pregnancies were obtained from Centro Materno-Infantil do Norte – Centro 
Hospitalar do Porto. All the procedures were reviewed and approved by the Research and 
Ethics Board of Centro Hospitalar do Porto. After multiple placenta washes, decidua was 
scraped from the chorionic membrane. The decidual tissue was then dissected and 
 enzymatically dissociated by collagenase (1 mg/ml). Red blood cells were lysed 
and the resulting suspension was filtered and centrifuged.  
The isolated cells were maintained in culture in DMEM/F12 medium supplemented 
with 10 % (v/v) of FBS treated with activated charcoal (FBS-CT), 1 % (v/v) of an antibiotic-
antimycotic (AB-AM) solution, 50 nM β-estradiol and 50 nM insulin and were incubated at 
37 °C in 95 % air/5 % CO2 humidified atmosphere. After 24 h, the non-adherent discarded 
and the adherent cells were grown to confluence and sub-cultured. The purity of primary 
HdF was confirmed by immunocytochemical analysis for the cytoskeletal proteins vimentin 
and cytokeratin-7, a fibroblast and an epithelial cell marker, respectively. 
Cells were cultured using the cell densities: 0,5x104 cells/well (final volume 200 μL) 
for 96-well plate, 2,5x104 cells/well (final volume 500 μL) for the 24-well plate and 5x104 
(final volume 2000 μL) for the 6-well plate. After adherence (24 h), the cells were washed 
with PBS and treated with the compounds, in cell culture medium with 2 % (v/v) FBS-CT.  
 
1.3  Cell viability assays  
 
To access cell viability it was used the tetrazolium salt [3-(4,5-dimetylthiazol-2-yl)-
2,5-dipheniltetrazolium bromide] (MTT) assay and measured the activity of the enzyme 
lactate dehydrogenase (LDH) in cell culture medium. For that, St-T1b cells were plated in 
96-well plates. After 24 h for adhesion, the medium was replaced with DMEM/F12 
medium with 2 % (v/v) FBS-CT and 1% AB-AM solution in the presence or absence of the 
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cannabinoids (0.01-50 μM), and the cells were incubated for 24 and 48 h. Equimolar 
concentrations of DMSO, the solvent vehicle of the compounds, was tested did not 
induced any cell viability alterations. The yellow tetrazole MTT (final concentration: 0,5 
mg/mL) was added, and the cells were incubated for 3 h at 37 °C. The formed purple 
formazan was dissolved in a solution of DMSO:isopropanol (3:1) and 
spectrophotometrically quantified at 540 nm by using a Multiskan Ascent microplate 
reader. MTT assay relies on the mitochondrial metabolism for the conversion of the yellow 
dye MTT on a purple dye formazan by viable cells. 
Cells supernatants were collected at 24 and 48 h to perform lactate 
dehydrogenase (LDH) assay. LDH is a cytosolic enzyme that is only released from cells 
into the extracellular space when the plasma membrane is disrupted. So, the release of 
LDH into the culture medium was evaluated by measurement of LDH activity by the use of 
the CytoTox 96 Non-Radioactive Cytotoxicity Assay Kit according to the manufacturer's 
instructions. Released LDH activity is measured with a coupled enzymatic assay, which 
results in conversion of a tetrazolium salt into a red formazan product. The intensity of 
colour formed is proportional to the number of lysed cells. Generation of Formazan is 
monitored by measuring absorbance at 490 nm using BioTek Power Wave XS plate 
reader.  
All the experiments were performed in at least three independent experiments and 
results were expressed as percentage of control/untreated cells.  
 
1.4  Cell proliferation assays 
 
To determine cell proliferation it was used the Sulforhodamine B (SRB) and BrdU 
assays. SRB is a fluorescent dye used for cell density determination via quantification of 
cellular proteins of cultured cells. The method of incubation was similar to the MTT assay 
till the end of incubation, and then the cells were fixed with trichloroacetic acid (final 
concentration: 40 %) for 1 h at 4 ºC and incubated with SRB (final concentration: 0.4 % in 
1 % acetic acid) for 30 min. The bound protein stain was solubilized in Tris-base (final 
concentration: 10 mM) and absorbance was assessed at 492 nm spectrophotometrically.  
Additionally, the thymidine analog BrdU (5-bromo-2’-deoxyuridine) proliferation 
assay was performed, following its incorporation by the newly synthesized genomic DNA. 
For that, St-T1b cells were plated in 96-well plates. After 24 h of culture, the medium was 
replaced with DMEM/F12 medium with 2 % FBS-CT and 1 % AB-AM solution in the 
presence or absence of cannabinoids (0.01-50 μM). The cells were labelled by the 
addition of BrdU (final concentration: 10 µM) for 28-30h. After the labelling period, the 
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cells were fixed and the anti-BrdU (final concentration: 1 µg/ml) antibody was added. The 
absorbance of the reaction product was measured at 450 nm using BioTek Power Wave 
XS plate reader.  
All experiments were performed in triplicate and in at least three independent 
experiments. Results were expressed as percentage of control/untreated cells. 
 
1.5  Morphological studies  
 
The morphological alterations caused by cannabinoids treatment were evaluated 
by phase-contrast microscopy, Giemsa and Höechst staining.  
The cells were cultured in 24-well culture plates with coverslips and treated with 
the different cannabinoids (25 μM of Δ9-THC, THJ-2201, JWH-122, AB-FUBINACA, UR-
144, 5F-PB-22, 2 and 5 μM of WIN) for 48 h.  
Giemsa staining is a variant of the Romanowsky-type stain. This technique allows 
the evaluation of cell morphology. Giemsa contains a mixture of methylene blue, eosin 
and Azure B (methylene azure B). The eosin Y dye stains the basic components of the 
cells. The methylene blue and azure B dyes stain the acidic components in shades 
between blue and purple. Cells were washed with PBS and fixed with methanol for 30 
minutes at 4 ºC. Then cells were washed with PBS and stained with Giemsa stain 
solution, diluted in distilled water (1:10) for 30 min. After washing with tap water, the 
coverslips with the stained cells were dehydrated and mounted in DPX mounting medium 
and observed under a bright field microscope (Eclipse E400, Nikon, Japan) equipped with 
image analysis software LeicaQwin.  
Höechst is a dye that emits blue fluorescence when bound to DNA. This staining 
allows the evaluation of nuclear morphology and the identification of apoptotic nuclei, 
which present chromatin condensation and fragmentation. After fixation with methanol for 
25 min at 4 ºC, the cells were exposed to 0.5 μg/mL Höechst 33342 (in PBS) for 20 min, 
washed with PBS, mounted in Fluoroshield mounting medium and observed under a 
fluorescence microscope equipped with an excitation filter with maximum transmission at 
360/400 nm (Eclipse CI, Nikon, Japan). Images were processed by Nikon NIS Elements 
Image Software.  
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1.6  Real-time Polymerase Chain Reaction (RT-PCR) 
 
To determine the amount of mitochondrial DNA (mtDNA) relative to nuclear DNA 
(nDNA), a quantitative real-time PCR was performed, by measuring the ratio of the 
mitochondrial gene, 16S rRNA, and a nuclear gene, GAPDH. For that, St-T1b cells were 
plated in 6-well plates. After 24 hours for adhesion, the medium was replaced with 
DMEM/F12 medium with 2 % FBS-CT and 1 % AB-AM solution in the presence or 
absence of cannabinoids (50 μM) for 48 h. Cells were collected in TRIsure reagent, and 
total DNA was extracted according to the manufacturer’s instructions. DNA was quantified 
in the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Inc., Wilmington, 
DE, USA). To determine THJ-2201, JWH-122 and AB-FUBINACA impact in the ratio of 
mtDNA/nDNA, DNA was amplified with specific primers: 16S rRNA and GAPDH. These 
reactions were carried out with KAPA SYBR FAST qPCR Master Mix 2x Kit (Kapa 
Biosystems, Woburn, MA, USA) in MiniOpticon Real-Time PCR Detection System (Bio-
Rad Laboratories, Hercules, CA, USA), according to kit protocol. Primer sequences and 
RT-PCR conditions are summarized in Table 1. 
 
Table 3 – RT-PCR conditions. Gene, primer sequences and temperatures used to obtain the ratio of 
mtDNA/nDNA.   
 
Gene Primer sequence (5’-3’) 
Annealing 
temperature (ºC) 
Melting 
temperature (ºC) 
16S rRNA 
Sense: ACTTTGCAAGGAGAGCCAAA 
Anti-sense: TGGACAACCAGCTATCACCA 
59 ºC 83,5 ºC 
GAPDH 
Sense: GGATGATGTTCTGGAAGAGCC 
Anti-sense: AACAGCCTCAAGATCATCAGC 
59 ºC 81,5 ºC 
    
1.7  Caspase -3/-7 activity  
 
To detect caspase -3/-7 activity, the cells were seeded in a 96-well white plate pre-
incubated for 30 min with the CB1 and CB2 antagonists, AM251 (1 μM), AM281 (2 μM) and 
AM630 (1 μM), respectively, and treated with the cannabinoids for 24 h. At the end of the 
incubation time, Caspase-Glo -3/-7 reagent was added to the cells according to the 
manufacturer's instructions. The plate was incubated at room temperature for 1 h and the 
resultant luminescence was measured in relative light luminescence units (RLU) using the 
96-well Microplate Luminometer (BioTek Instruments, Winooski, VT, USA). The results 
are expressed in percentage, comparing caspase -3/-7 activities of cannabinoid-treated 
cells with the untreated cells.  
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1.8  Zymography 
 
To determine the activity of metalloproteinases (MMPs) a zymography was 
performed. For that, St-T1b cells were plated in 24-well plates. After 24 h of culture, the 
medium was replaced by DMEM/F12 medium with 2 % FBS and 1 % AB-AM solution and 
12 h before experiment the medium was replaced with DMEM/F12 medium with 2 % FBS-
CT and 1 % AB-AM in the presence or absence of cannabinoids (25 μM). After 48h the 
supernatants were collected and the Bradford assay was performed to quantify protein 
concentration. Then, equal amounts of total proteins (5 μg) were separated without 
heating and without β-mercaptoethanol on a 10 % SDS-polyacrylamide gel containing 1% 
gelatine. The gels were washed, incubated in developing buffer for 16 h at 37 ºC and 
stained with 5 % Coomassie blue R250. Bands representing gelatinase activity were 
photographed and analysed by densitometry.    
 
1.9  UPLC-MS/MS 
 
To determine the concentration of prostaglandin E2 in term placenta supernatant 
and tissue, an ultra-performance liquid chromatography-mass spectrometry (UPLC-
MS/MS) analysis was performed. Explants of decidua from term placentas were collected 
within two hours after delivery and plated in 6-well plates with DMEM/F12 medium with 2 
% FBS-CT and 1 % AB-AM. After two hours, the medium was replaced in the presence 
and absence of cannabinoids (25 μM). After 24 h, supernatant and tissue were collected 
and frozen at -80 ºC.  
 
1.9.1 Sample preparation  
 
In the day of the experiment, prostaglandin extraction was performed. In 
supernatant, 500 μl of sample were added to 0.4 g of MgSO4, 0.1 g of NaCl, 500 μl of 
ethyl acetate and 20 μl of PGE2-d4, and centrifuge for 15 min at 3500 xg. At the end of 
centrifugation, supernatant was collected and evaporated to dryness under nitrogen. The 
samples were reconstituted with 100 μl of methanol. Tissue extraction was performed by 
adding 500 μl of methanol, 20 μl of PGE2-d4 and C18 to a small fragment of tissue, and 
centrifuge for 30 min at 3500 xg. At the end of centrifugation, supernatant was collected 
and evaporated to dryness under nitrogen. Samples were reconstituted with 100 μl of 
acetonitrile and injected in the UPLC-MS/MS (10 μl injection volume). 
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1.9.2 UPLC MS/MS analysis  
 
Separation and quantification of the target analyte was performed by using a liquid 
chromatography Acquit UPLC system interfaced to a triple quadrupole mass selective 
detector Micromass Quattro micro API, (Waters, Milford, MA, USA). The injection volume 
was set at 10 μl. The chromatographic separation was carried out with a BEH C18 column 
(1.6 μm, 2.1 mm x 150 mm (i.d.)) from ACQUITY UPLC, at a flow rate of 0.20 ml/min. The 
mobile phases were (A) 5 % ammonium acetate (5 mM) in ultra-pre MilliQ water and (B) 
MeOH (UPLC grade, VWR, Radnor, PA, USA) in an isocratic gradient. Mass spectrometry 
analysis was performed with an electrospray ionization (ESI) source in the negative (ESI-) 
ion mode for all the analytes. Nitrogen was used as the nebulizer gas. The optimum MS 
parameters were as follows: capillary, 3.00 kV; extractor, 2 V; RF lens, 0.5 V; source 
temperature, 150 ºC; desolvation temperatures, 350 ºC; desolvation gas flow, 350.0L/h; 
cone gas flow, 60.0 L/h; LM resolution, 13.0; ion energy, 1.0; entrance, 1; exit, 2; 
multiplier, 650. All analyses were done in multiple reaction monitoring (MRM) mode. 
 
1.10  Statistical analysis  
 
Statistical data analysis was carried out by one or two way ANOVA, followed by 
the Tukey post hoc test to make pairwise comparisons of individual means when 
significance was indicated, using Graphpad Prism 6.0 (GraphPad PRISM v. 6.0, 
GraphPad Software, Inc., San Diego, CA, USA). Graphs were also drawn using Graphpad 
Prism 6.0. The results are the mean of at least three independent experiments carried out 
in triplicate. Data are expressed as the mean±SEM, and differences were considered to 
be statistically significant at P<0.05.  
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1.1 Effects of synthetic cannabinoids on endometrial 
stromal cell viability  
 
To investigate the effects of synthetic cannabinoids, WIN 55,212-2, THJ-2201, 
JWH-122, AB-FUBINACA, UR-144 and 5F-PB-22, in the viability of the St-T1b cell line 
and HdF primary cultures a MTT assay was performed using concentrations ranging from 
0.01 to 50 µM, and treatments of 24 and 48 h. This assay quantifies the mitochondrial 
metabolism that converts the yellow MTT into the purple formazan by viable cells. 
The treatment of St-T1b cells with THJ-2201, UR-144 and 5F-PB-22 did not affect 
cell viability. On the other hand, JWH-122, AB-FUBINACA and WIN 55,212-2 induced 
different effects in cell viability. The first two treatments led to an increase in mitochondrial 
activity in treatments with the higher concentrations, while WIN induced a significant 
decrease that was dose and time-dependent (Figure 12).      
 
 
Figure 12 – Effects of synthetic cannabinoids in St-T1b cells. Cell viability of treated cells with different 
concentrations (0.01- 50 µM) of synthetic cannabinoids, at 24 and 48 h of treatment, assessed by MTT assay. 
(***P < 0.001, **P < 0.01, *P < 0.05 vs. Control).  
 
In primary cultures, contrary to THJ-2201, that did not cause any alterations in cell 
viability, JWH-122, AB-FUBINACA, UR-144 and 5F-PB-22 induced an increase in 
mitochondrial activity dependent on time and concentration. WIN, like in the St-T1b cell 
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line, caused a reduction in cell viability. After 48 h it was obtained a drastic reduction for 
the concentrations between 0.1 and 25 µM (Figure 13). 
 
 
 
Figure 13 – Effects of synthetic cannabinoids in HdF cells. Cell viability of treated cells with different 
concentrations (0.01- 50 µM) of synthetic cannabinoids, at 24 and 48 h of treatment, assessed by MTT assay. 
(***P < 0.001, **P < 0.01, *P < 0.05 vs. Control).   
 
1.2 Effects of synthetic cannabinoids in endometrial stromal 
cell morphology 
 
Giemsa staining was performed to study if the synthetic cannabinoids treatments 
affected cell morphology. St-T1b and HdF cells were treated for 48 h with 25 µM of THJ-
2201, JWH-122, AB-FUBINACA, UR-144 and 5F-PB-22 and with 2 and 5 µM of WIN 
55,212-2 (Figure 14 and 15). 
Contrary to THJ-2201, JWH-122, AB-FUBINACA, UR-144 and 5F-PB-22, WIN 
55,212-2 induced a dramatic reduction in cell density and chromatin condensation (Figure 
16). 
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Figure 14 – Effects of synthetic cannabinoids in St-T1b cell morphology. Cell morphology of treated cells 
with 25 µM of different synthetic cannabinoids for 48 h was assessed by Giemsa staining. 
 
 
 
Figure 15 – Effects of synthetic cannabinoids in HdF cell morphology. Cell morphology of treated cells 
with 25 µM of different synthetic cannabinoids for 48 h was assessed by Giemsa staining. 
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Figure 16 – Effects of WIN 55,212-2 in cell morphology. Cell morphology of treated cells with 2 and 5 µM 
for 48 h was assessed by Giemsa staining. Arrows represent chromatin condensation. 
 
1.3 Effects of synthetic cannabinoids on endometrial 
stromal cell proliferation 
 
The Sulforhodamine B assay was performed in order to clarify the results obtained 
with the MTT assay, since it is based on the measurement of cellular protein content, and 
thus used for cell density quantification. Similarly to MTT assay, cells were treated with 
synthetic cannabinoids for 24 and 48 h (Figure 17). 
In the cell line, THJ-2201, JWH-122 and AB-FUBINACA showed an increase in 
cell proliferation with the concentrations of 1, 50 and 0.1 µM at 48 h of treatment, 
respectively. In the HdF cells, only THJ-2201 and JWH-122 caused changes in cell 
proliferation after 48 h of treatment. 
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Figure 17 – Effects of synthetic cannabinoids in cell density. Cell protein quantification of treated cells 
with different concentrations (0.01- 25 µM) of different synthetic cannabinoids, at 24 and 48 h of treatment, 
assessed by SRB assay. (***P < 0.001, *P < 0.05 vs. Control). 
 
Due to the discrepant results obtained in the MTT and in the Sulforhodamine B 
assay, another proliferation assay was performed, the BrdU assay in which this 
nucleoside incorporates in the DNA synthesized by new cells. After incorporation, the 
nucleoside is detected with an anti-BrdU antibody, allowing to detected cellular 
proliferation. The synthetic cannabinoids THJ-2201, JWH-122 and AB-FUBINACA did not 
induce alterations in cell proliferation in both cells models (Figure 18).   
 
 
Figure 18 – Effects of synthetic cannabinoids in cell proliferation. Cell proliferation of treated cells with 
different concentrations (0.01- 25 µM) of different synthetic cannabinoids, at 24 and 48 hours of treatment, 
assessed by BrdU assay. 
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1.4 Effect of synthetic cannabinoids in endometrial 
stromal cells mitochondrial number 
 
In order to understand the results obtained by the MTT assay and by the 
proliferation assays, it was investigated the effects of THJ-2201, JWH-122 and AB-
FUBINACA in mitochondrial number after 48 h of treatment. Thus the ratio of 
mtDNA/nDNA was assessed, through RT-PCR using specific primers for 16S rRNA and 
GAPDH as indicated in Table 3. None of the synthetic cannabinoids caused alterations in 
the mitochondrial number (Figure 19). 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19 – Effects of synthetic cannabinoids in mitochondrial number. The ratio of mtDNA and nDNA in 
endometrial stromal cell line and in primary cultures of human decidual fibroblast cells obtained by RT-PCR. 
 
1.5 Effect of synthetic cannabinoids in endometrial 
stromal cells cannabinoid receptors 
 
 To investigate if the effects induced by the synthetic cannabinoids were through 
the cannabinoid receptors, cells were treated with these molecules in the presence and 
absence of CB1 and CB2 antagonists. The CB2 antagonist was only used in the primary 
cells cultures because the St-T1b cell line does not express CB2 receptor. 
 The increase in mitochondrial activity induced by the synthetic cannabinoid AB-
FUBINACA seem to be through the cannabinoid receptor 1, since it appears to be 
reverted by CB1 antagonists in both cell lines (Figures 20 and 21).  
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Figure 20 – Effects of synthetic cannabinoids in St-T1b cell viability in combination with CBR 
antagonists. Cell viability of treated cells with 50 µM after 30 min of incubation with CB1 antagonists (AM251; 
AM281). 
 
 
Figure 21 – Effects of synthetic cannabinoids in HdF cell viability in combination with CBR 
antagonists. Cell viability of treated cells with 50 µM after 30 min of incubation with CB1 antagonists (AM251; 
AM281) and CB2 antagonists (AM630). (**P < 0.01, *P < 0.05 vs. Control). 
 
1.6 Effects of synthetic cannabinoids in endometrial 
stromal cell LDH release 
 
As WIN 55,212-2 caused a drastic reduction in cell viability it was evaluated if this 
cannabinoid was cytotoxic, by determining the activity of LDH. LDH is a cytosolic enzyme 
that is only released from cells after membrane disruption, being a biomarker of cell 
cytotoxicity. WIN 55,212-2 only caused an increase in LDH release, in both cells at 10 and 
25 µM (Figure 22).  
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Figure 22 – Effects of WIN 55,212-2 in LDH activity. LDH activity of treated cells with different 
concentrations (0.01-25 µM) at 24 and 48 h of treatment. (***P < 0.001, **P < 0.01, *P < 0.05 vs. Control). 
 
1.7 Effect of WIN 55,212-2 in endometrial stromal cells 
chromatin condensation 
 
To confirm the chromatin condensation and nuclei alterations detected in cells 
stained with Giemsa, Höechst staining was performed. The chromatin condensation, 
which suggests an apoptotic process, was also observed and was accompanied by a 
decrease in cell density (Figure 23). 
 
 
 
 
Figure 23 – Effects of WIN 55,212-2 in chromatin condensation. Cell morphology of treated cells with 2 
and 5 µM after 48 h of treatment was assessed by Höechst staining. Arrows represent chromatin 
condensation. 
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1.8 Effects of WIN 55,212-2 in endometrial stromal cell 
apoptosis 
 
Caspases are endoproteases that play essential roles in programmed cell death, 
acting as initiator or executioner caspases. Caspase -3 and -7 are executioner caspases. 
To investigate the reduction in cell viability induced by WIN 55,212-2 and 
apoptosis suggested by the Höechst staining, caspase -3/-7 activities were quantified at 5 
µM of WIN 55,212-2, since this concentration caused a decrease in mitochondrial activity 
but did not induce an increase in LDH release. The reduction in cell viability caused by 
WIN 55,212-2 in St-T1b cells was not accompanied by an increase in caspase -3/-7 
activities nor reverted by the pre-treatment with CB1 antagonists. Interestingly, in primary 
cultures, 5 µM of WIN 55,212-2 caused an increase in caspase activity, which was 
partially reversed by co-incubation with CB1 antagonist AM281 (Figure 24). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24 – Effects of WIN 55,212-2 in caspase -3/-7 activities. Cells were treated with WIN 55,212-2 in 
combination with CB1 and CB2 antagonists, AM251 or AM281 and AM630, respectively. (*P < 0.05 vs. 
Control). 
 
1.9 Effect of WIN 55,212-2 in endometrial stromal cells 
cannabinoid receptors 
 
To investigate if WIN 55,212-2 affected cell viability through the cannabinoid 
receptors, cells were treated in the presence and absence of CB1 and CB2 antagonists. 
 The decrease in cell viability induced by WIN 55,212-2 seems to be influenced 
through the cannabinoid receptor 1, as treatment with AM281 attenuated the effects 
induced by WIN 55.212-2 (Figure 25). 
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Figure 25 – Effects of WIN 55,212-2 in cell viability in combination with CBR antagonists. Cell viability of 
cells pre-incubated with CB1 antagonists (AM251; AM281) and CB2 antagonists (AM630) for 30 minutes were 
treated with 5 µM of WIN 55,212-2 during 48 h. 
 
1.10 Effects of cannabinoids in endometrial stromal cells 
function 
 
1.10.1 Matrix metalloproteinase 9 activity by 
zymography 
 
Various proteinases and enzymes are expressed in the human endometrium, 
being the MMP family responsible for the extracellular matrix proteolysis during the 
menstrual cycle. This family of proteinases is also responsible for the degradation and 
remodelling of the endometrium necessary to implantation. 
To determine the activity of matrix metalloproteinase 9 after 48 h of treatment with 
different synthetic cannabinoids, and the phytocannabinoid Δ9-THC as a control, a 
zymography was performed. Although, a decrease in MMP-9 activity occurred in cells 
treated with WIN 55,212-2, Δ9-THC, UR-144 and 5F-PB-22 in both cells, none of the 
different treatments caused significant changes in the activity of MMP-9 as observed by 
the densitometric analysis (Figure 26). 
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Figure 26 – Effects of synthetic cannabinoids in MMP-9 activity. A zymography was performed with six 
different synthetic cannabinoids and a phytocannabinoid. Densitometric analysis is graphically represented 
and representative figures of zymography results are shown. 
 
1.10.2 Prostaglandin E2 levels by UPLC-MS/MS 
 
 As prostaglandins (PGs) are synthesized by the endometrial stromal (the precursor 
of the decidual cell), epithelial and endothelial cells across the menstrual cycle, 
experiments were performed to determine whether synthetic cannabinoids may affect 
prostaglandin E2 production in the supernatant and tissue from term placenta explants. 
Preliminary results (n=3) showed that, after 24 h of treatment, in explants 
supernatant, contrary to the Δ9-THC that caused an increase in PGE2, THJ-2201 and AB-
FUBINACA induced a reduction in its production. In the tissue, WIN 55,212-2 and AB-
FUBINACA induced an increase in PGE2 production, whilst THJ-2201 caused a decrease 
in PGE2 levels. The increase in the PGE2 levels caused by AB-FUBINACA, in the tissue, 
may explain the reduction in the supernatant. 
Although statistically significance was not achieved, probably due to the small 
number of samples, these effects were more evident within tissue PGE2 production 
(Figure 27).   
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 
- 43 - 
 
 
 
 
 
 
 
 
 
 
 
Figure 27 – Effects of synthetic cannabinoids in PGE2 concentration in supernatant and tissue of term 
placenta. After 24 h of treatments, no significant alterations in PGE2 levels were observed, even though 
cannabinoids caused changes in PGE2 production.   
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Cannabis is the most abused illicit substance in the world, having nearly 80 million 
people of the EU consumed at least once. Its use is spread across all ages, from the 
occasional to regular users. Cannabis abuse is the most frequent reason for seeking drug 
treatment, and it is responsible for a fair amount of drug-related emergencies (57). 
However, restrictions to its use has raised new concerns about the consumption of new 
psychoactive substances with unclear legislation, like synthetic cannabinoids (56).  
The drug most commonly used by women in childbearing age is Cannabis, and 
this substance seems to affect negatively female endocrinologic and reproductive 
functions (115). In addition, synthetic cannabinoids production and consumption has been 
increasing in the past years. However, their effects are unknown to health and in particular 
to reproduction. 
In this work, the effects of six synthetic cannabinoids in endometrial stromal cells 
were studied in a cell line, St-T1b, and in primary cultures of human decidual fibroblasts, 
HdF. These two cell types complement each other, which makes them good cell models 
to study these effects. THJ-2201, an analog of the synthetic cannabinoid AM-2201, did not 
induce any alterations in cell viability, morphology, as well as in cell proliferation of St-T1b 
cell line and primary decidual fibroblasts. Cytotoxicity studies with the synthetic 
cannabinoid AM-2201 are scarce, nevertheless, a recent study described that this 
compound induces cytotoxicity after 2 hours of treatment but at a concentration of 30 µM 
in primary cultures of neuronal cells (116).  
On the other hand, AB-FUBINACA, UR-144, 5F-PB-22 and JWH-122, analogs of 
JWH-018, induced an increase in MTT metabolism at high concentrations (10-50 µM). 
Interestingly, this effect was not accompanied by an increase in cell proliferation as 
determined by the SRB and BrdU assays. So, as the MTT assay measured mitochondrial 
activity, the involvement of mitochondria was investigated by quantifying the ratio of 
mtDNA versus nDNA, to verify if the number of mitochondria varies between treatments. 
However, no significant differences were observed, which suggests that no alterations in 
the mitochondrial number occurred and the effects observed in the MTT assay may result 
from increased mitochondrial activity. 
Most of the synthetic cannabinoids studied in this work are analogs of JWH-018. 
Couceiro et al. studied the cytotoxicity of JWH-018 in cells with and without CB1, a human 
kidney cell line (HEK293T) and human cell line of neuroblastoma (SH-SY5Y), and 
observed that this compound did not significantly affect cell viability in both cells, although 
a dose-dependent increase in MTT metabolism was also observed (117). A similar effect 
was described for WIN 55,212-2 by Aguirre-Rueda et al., in primary cultures of cortical 
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astrocytes (118). This effect was associated to a cytoprotective role attributed to 
cannabinoids.  
Our results suggest that mitochondrial activity may be influenced by the 
compounds, particularly by activation of the cannabinoid receptor CB1 in mitochondrial 
membranes, as described in brain neuronal mitochondria membrane. In this study, it was 
suggested that it directly regulates mitochondrial metabolism (119), through modulation of 
complex I activity, regulating cAMP levels and PKA activity. These molecules may 
modulate the organelle metabolism. Nevertheless, these effects may also be due to 
activation of other non-CB1/CB2 cannabinoid receptors (120) that are yet to be fully 
understood. This may also be one explanation for the results obtained with the CB1/CB2 
antagonists. CB1 antagonist was used in both the cell line and primary cells, however CB2 
antagonist was only tested in HdF, because, as referred, the St-T1b cell line does not 
express this receptor (121).  In fact, the co-incubation with CB1/CB2 antagonists did not 
reverse the effects induced by synthetic cannabinoids in our study. Fišar et al. also 
described a non-receptor-mediated cannabinoid mechanisms involved in the regulation of 
mitochondrial respiration (122). 
The other synthetic cannabinoid, WIN 55,212-2 is an aminoalkylindole-type and a 
full agonist of CB1 receptor (123). In our work, WIN 55,212-2 caused a decrease in cell 
viability as revealed by MTT assay in a dose and time-dependent way. For high 
concentrations, 10 µM in primary human decidual fibroblast and 25 µM in St-T1b cell line, 
these effects were accompanied by an increase in LDH release, suggesting the 
occurrence of a cytotoxic effect for these concentrations. WIN 55,212-2 also induced 
morphological alterations, in both models, such as chromatin condensation, accompanied 
with decreased cell density.  
In order to confirm the apoptotic cell death suggested by the morphologic 
alterations, caspase -3/-7 was quantified. It was observed a dramatic increase in this 
effector caspase activity, being this increment more significant in primary cells. It was also 
verified that the caspase activity was partially reversed by the CB1 antagonist AM281, 
suggesting that WIN 55,212-2 induced apoptosis through CB1 activation. These effects 
are in concordance with a previous study of Kessler et al., which described apoptosis in 
decidualized fibroblasts induced by WIN 55,212-2 in concentrations ranging from 0.1 to 10 
µM. These affects were also dependent on CB1 activation (124). Furthermore, the cellular 
morphological alterations induced by WIN 55,212-2 in both cell line and primary cultures 
were also observed by Giuliano et al. in liver hepatocellular cells (125). 
In accordance to our results, WIN 55,212-2 has already been shown to induce 
apoptosis in other cell models, like hepatocellular carcinoma cells (126) and HepG2 cells 
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(125). In hepatocellular carcinoma cells, cell death was via mitochondrial pathway, with a 
significant decrease in mitochondrial membrane potential, and increase in caspase -3, -8 
and -9 activities, suggesting the involvement of mitochondria. In HepG2 cells, a human 
liver cancer cell line, apoptosis was accompanied by the up-regulation of the death 
signalling factors Bax, which, subsequently, led to a mitochondrial dysfunction and 
activation of executioner caspase -3 and -6, and activation of JNK/p38 MAPK pathway. 
As no significant effects seem to be induced by synthetic cannabinoids in the 
viability and proliferation of endometrial cells, we investigated if these compounds caused 
any interference at the functional level, interacting with enzymes or proteins important to 
the normal function of the endometrium. Regulation of MMPs production and activation, 
and subsequent degradation and tissue remodeling, is crucial for the fast and extensive 
tissue destruction occurring during the menstrual cycle (127), as the receptivity of the 
endometrium to implantation is one of the most important processes to accomplish a 
successful pregnancy. So, normal proliferation of endometrial stromal cells and 
subsequent decidualization, along with extracellular decidual matrix remodeling are 
necessary (67). Another important part for a normal maintenance of the endometrium is 
the production of Prostaglandins (PGs), which have a key role in numerous aspects of 
pregnancy, including term and preterm delivery. Its importance is due to arachidonic acid, 
a precursor of prostaglandin production and a final product of endocannabinoid hydrolysis, 
which means that any imbalance in the endocannabinoid system may affect PG 
production (128).  
One of the most important enzymes responsible for remodeling of the extracellular 
matrix is the MMP family, which is in charge of degradation of ECM to allow implantation. 
In this work, the activity of MMP-9 did not present significant differences between 
treatments and the control group, although a slight decrease in gelatinase activity was 
detected in the cells treated with WIN 55,212-2, Δ9-THC, UR-144 and 5F-PB-22. The 
decrease of MMPs in the endometrium may affect the decidualization of the stromal cells 
and even the implantation of the blastocyst, as described by Rechtman et al. They 
demonstrated that inhibition of MMPs affected decidualization, causing a reduction in the 
total decidua area (129).  
Even though most studies were performed in cancer cells, it was observed a 
decrease in MMP -2 and -9 activities. Blázquez et al. using rat glioma cells and human 
tumor samples showed that the expression of MMP-2 was inhibited by Δ9-THC and by a 
synthetic cannabinoid (JWH-133), via the sphingolipid ceramide regulation (130). Also, 
Preet et al. demonstrated that MMP-9 secretion and activity was significantly inhibited by 
WIN 55,212-2 and JWH-015 in non-small cell lung cancer cell line (NSCLC) and 
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adenocarcinomic human alveolar basal epithelial cells (A549). However, this inhibition 
was reversed by a GPCR inhibitor, implicating the involvement of CB1 and CB2 (131). 
Nevertheless, no studies have addressed the role of synthetic cannabinoids on MMP in 
the endometrium. 
PGs that are members of the eicosanoid family and their synthesis involve the 
cyclooxygenase enzyme (COX), which is present in numerous tissues and cell types. So, 
this enzyme is responsible for production of PGs which are essential to normal 
physiological functions. COX-2 expression and PGE2 synthesis were already associated 
to the modulation of cellular proliferation, resistance to apoptosis and cell differentiation. 
PGE2 is also important for a normal physiological function of the endometrium with 
maximum synthesis during the menstrual and proliferative phases, and is produced in 
epithelial, stromal and endothelial cells, across the menstrual cycle (132).  
In our work, WIN 55,212-2, Δ9-THC, UR-144 and 5F-PB-22 induced an increase in 
PGE2 production, whereas THJ-2201, JWH-122 and AB-FUBINACA induced a reduction, 
with a more evident effect in tissue than in the supernatant of decidua explants from term 
placenta. These results may be explained by the results described by Mitchell et al., who 
studied the effects of endocannabinoids and CP 55,940, a synthetic cannabinoid, in 
decidua explants. They showed that AEA significantly reduced PGE2 production while CP 
55,940 caused a slight increase. This study also suggested that the effects of 
cannabinoids on PG production in placenta were through activation of CB1 and induction 
of COX-2 (128). Mestre et al. also studied the effects of WIN 55,212-2 in murine 
endothelial brain cells, showing that PGE2 production increased. It was also observed that 
WIN 55,212-2 induced the production of PGE2 that was due to COX-2, and that these 
effects were dose-dependent and mediated by mechanisms independent of CB1 and CB2 
activation (133). These studies demonstrate that these new substances may interact with 
the production of PGs, affecting fertility.     
 In summary, we present evidences for the first time that synthetic cannabinoids 
may affect endometrial stromal cell stability, as well as have implications in PGs 
production, which are important for a myriad of physiological functions in the endometrium 
and in the placenta. We also describe that these substances may affect MMP-9 activity, 
influencing endometrial extracellular matrix degradation. Furthermore, WIN 55,212-2 
induced apoptosis through CB1 activation, and this may interfere with endometrial stromal 
cell remodeling. These effects may be dependent on the chemical structure and thus, the 
CB affinity that induce activation of different signaling pathways, justifying the effects 
observed by WIN 55,212-2 in relation to cell viability. 
Discussion 
- 49 - 
 
The increased use of synthetic cannabinoids by young people is a today’s society 
problem with important impact on fertility. Although most of the problems that may result 
from its consumption are unknown, in this work we evidenced some signaling pathways 
that may affect fertility. Thus, this work may be a starting point to begin to understand the 
impact of this emerging class of substances and their effects in human fertility.  
  
 
  
Chapter VI - References 
References 
- 51 - 
 
1. Sun X, Dey SK. Aspects of endocannabinoid signaling in periimplantation biology. 
Molecular and cellular endocrinology. 2008;286(1-2 Suppl 1):S3-11. 
2. Sun X, Dey SK. Synthetic cannabinoids and potential reproductive consequences. 
Life sciences. 2014;97(1):72-7. 
3. Mechoulam R, Hanus L. A historical overview of chemical research on 
cannabinoids. Chemistry and physics of lipids. 2000;108(1-2):1-13. 
4. Gaoni YM, R. Isolation, structure and partial synthesis of an active constituent of 
hashish. Journal of the American Chemical Society. 1964;86:1646-7. 
5. Dewey WL. Cannabinoid pharmacology. Pharmacological reviews. 
1986;38(2):151-78. 
6. Paria BC, Dey SK. Ligand-receptor signaling with endocannabinoids in 
preimplantation embryo development and implantation. Chemistry and physics of lipids. 
2000;108(1-2):211-20. 
7. Jaques SC, Kingsbury A, Henshcke P, Chomchai C, Clews S, Falconer J, et al. 
Cannabis, the pregnant woman and her child: weeding out the myths. Journal of 
perinatology : official journal of the California Perinatal Association. 2014;34(6):417-24. 
8. Seely KA, Prather PL, James LP, Moran JH. Marijuana-based Drugs: Innovative 
Therapeutics or Designer Drugs of Abuse? Molecular Interventions. 2011;11(1):37-8. 
9. Gertsch J, Pertwee RG, Di Marzo V. Phytocannabinoids beyond the Cannabis 
plant - do they exist? British journal of pharmacology. 2010;160(3):523-9. 
10. Seely KA, Prather PL, James LP, Moran JH. Marijuana-based drugs: innovative 
therapeutics or designer drugs of abuse? Molecular interventions. 2011;11(1):36-51. 
11. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a 
cannabinoid receptor and functional expression of the cloned cDNA. Nature. 
1990;346(6284):561-4. 
12. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral 
receptor for cannabinoids. Nature. 1993;365(6441):61-5. 
13. Di Marzo V. The endocannabinoid system: its general strategy of action, tools for 
its pharmacological manipulation and potential therapeutic exploitation. Pharmacological 
research. 2009;60(2):77-84. 
14. Park B, Gibbons HM, Mitchell MD, Glass M. Identification of the CB1 cannabinoid 
receptor and fatty acid amide hydrolase (FAAH) in the human placenta. Placenta. 
2003;24(10):990-5. 
15. Dennedy MC, Friel AM, Houlihan DD, Broderick VM, Smith T, Morrison JJ. 
Cannabinoids and the human uterus during pregnancy. American journal of obstetrics and 
gynecology. 2004;190(1):2-9; discussion 3A. 
16. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. 
International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. 
Pharmacological reviews. 2002;54(2):161-202. 
17. McAllister SD, Glass M. CB(1) and CB(2) receptor-mediated signalling: a focus on 
endocannabinoids. Prostaglandins, leukotrienes, and essential fatty acids. 2002;66(2-
3):161-71. 
18. Pertwee RG, Ross RA. Cannabinoid receptors and their ligands. Prostaglandins, 
leukotrienes, and essential fatty acids. 2002;66(2-3):101-21. 
19. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, et al. 
Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 
and CB2 receptors. Molecular pharmacology. 1995;48(3):443-50. 
20. Shire D, Carillon C, Kaghad M, Calandra B, Rinaldi-Carmona M, Le Fur G, et al. 
An amino-terminal variant of the central cannabinoid receptor resulting from alternative 
splicing. The Journal of biological chemistry. 1995;270(8):3726-31. 
21. Fonseca BM, Costa MA, Almada M, Correia-da-Silva G, Teixeira NA. Endogenous 
cannabinoids revisited: a biochemistry perspective. Prostaglandins & other lipid 
mediators. 2013;102-103:13-30. 
References 
- 52 - 
 
22. Battista N, Rapino C, Di Tommaso M, Bari M, Pasquariello N, Maccarrone M. 
Regulation of male fertility by the endocannabinoid system. Molecular and cellular 
endocrinology. 2008;286(1-2 Suppl 1):S17-23. 
23. Cacciola G, Chioccarelli T, Ricci G, Meccariello R, Fasano S, Pierantoni R, et al. 
The endocannabinoid system in vertebrate male reproduction: a comparative overview. 
Molecular and cellular endocrinology. 2008;286(1-2 Suppl 1):S24-30. 
24. Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, et al. 2-arachidonyl 
glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proceedings of 
the National Academy of Sciences of the United States of America. 2001;98(7):3662-5. 
25. Bisogno T, Melck D, Bobrov M, Gretskaya NM, Bezuglov VV, De Petrocellis L, et 
al. N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of 
anandamide inactivation with cannabimimetic activity in vitro and in vivo. The Biochemical 
journal. 2000;351 Pt 3:817-24. 
26. Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, et al. 
An endogenous capsaicin-like substance with high potency at recombinant and native 
vanilloid VR1 receptors. Proceedings of the National Academy of Sciences of the United 
States of America. 2002;99(12):8400-5. 
27. Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, et al. 
Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the 
CB1 receptor. The Journal of pharmacology and experimental therapeutics. 
2002;301(3):1020-4. 
28. Bisogno T, Melck D, De Petrocellis L, Di Marzo V. Phosphatidic acid as the 
biosynthetic precursor of the endocannabinoid 2-arachidonoylglycerol in intact mouse 
neuroblastoma cells stimulated with ionomycin. Journal of neurochemistry. 
1999;72(5):2113-9. 
29. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular 
characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 
1996;384(6604):83-7. 
30. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, et al. Brain 
monoglyceride lipase participating in endocannabinoid inactivation. Proceedings of the 
National Academy of Sciences of the United States of America. 2002;99(16):10819-24. 
31. Karlsson M, Contreras JA, Hellman U, Tornqvist H, Holm C. cDNA cloning, tissue 
distribution, and identification of the catalytic triad of monoglyceride lipase. Evolutionary 
relationship to esterases, lysophospholipases, and haloperoxidases. The Journal of 
biological chemistry. 1997;272(43):27218-23. 
32. McPartland JM, Matias I, Di Marzo V, Glass M. Evolutionary origins of the 
endocannabinoid system. Gene. 2006;370:64-74. 
33. Sawzdargo M, Nguyen T, Lee DK, Lynch KR, Cheng R, Heng HH, et al. 
Identification and cloning of three novel human G protein-coupled receptor genes GPR52, 
PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain research 
Molecular brain research. 1999;64(2):193-8. 
34. Taylor AH, Ang C, Bell SC, Konje JC. The role of the endocannabinoid system in 
gametogenesis, implantation and early pregnancy. Human reproduction update. 
2007;13(5):501-13. 
35. Sun X, Dey SK. Endocannabinoid signaling in female reproduction. ACS chemical 
neuroscience. 2012;3(5):349-55. 
36. Beltramo M, Piomelli D. Carrier-mediated transport and enzymatic hydrolysis of the 
endogenous cannabinoid 2-arachidonylglycerol. Neuroreport. 2000;11(6):1231-5. 
37. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nature 
reviews Drug discovery. 2008;7(5):438-55. 
38. Pertwee RG. The therapeutic potential of drugs that target cannabinoid receptors 
or modulate the tissue levels or actions of endocannabinoids. The AAPS journal. 
2005;7(3):E625-54. 
References 
- 53 - 
 
39. Fine PG, Rosenfeld MJ. The endocannabinoid system, cannabinoids, and pain. 
Rambam Maimonides medical journal. 2013;4(4):e0022. 
40. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. 
Clinical pharmacokinetics. 2003;42(4):327-60. 
41. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-
terpenoid entourage effects. British journal of pharmacology. 2011;163(7):1344-64. 
42. Jarbe TU, Deng H, Vadivel SK, Makriyannis A. Cannabinergic aminoalkylindoles, 
including AM678=JWH018 found in 'Spice', examined using drug (Delta(9)-
tetrahydrocannabinol) discrimination for rats. Behavioural pharmacology. 2011;22(5-
6):498-507. 
43. Little PJ, Compton DR, Johnson MR, Melvin LS, Martin BR. Pharmacology and 
stereoselectivity of structurally novel cannabinoids in mice. The Journal of pharmacology 
and experimental therapeutics. 1988;247(3):1046-51. 
44. Mechoulam R, Feigenbaum JJ, Lander N, Segal M, Jarbe TU, Hiltunen AJ, et al. 
Enantiomeric cannabinoids: stereospecificity of psychotropic activity. Experientia. 
1988;44(9):762-4. 
45. Wiley JL, Marusich JA, Lefever TW, Grabenauer M, Moore KN, Thomas BF. 
Cannabinoids in disguise: Delta9-tetrahydrocannabinol-like effects of 
tetramethylcyclopropyl ketone indoles. Neuropharmacology. 2013;75:145-54. 
46. EMCDDA. Perspectives on Drugs: Synthetic cannabinoids in Europe. 2016. 
47. Thakur GA, Nikas SP, Makriyannis A. CB1 cannabinoid receptor ligands. Mini 
reviews in medicinal chemistry. 2005;5(7):631-40. 
48. EMCDDA. Synthetic cannabinoids and 'Spice' drug profile 2015 [updated 8 
January 2015]. Available from: http://www.emcdda.europa.eu/publications/drug-
profiles/synthetic-cannabinoids. 
49. ACMD. Consideration of the major cannabinoid agonists. 2009. 
50. Hermanns-Clausen M, Kneisel S, Szabo B, Auwarter V. Acute toxicity due to the 
confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. 
Addiction. 2013;108(3):534-44. 
51. Kemp AM, Clark MS, Dobbs T, Galli R, Sherman J, Cox R. Top 10 Facts You 
Need to Know About Synthetic Cannabinoids: Not So Nice Spice. The American journal of 
medicine. 2016;129(3):240-4 e1. 
52. Znaleziona J, Ginterova P, Petr J, Ondra P, Valka I, Sevcik J, et al. Determination 
and identification of synthetic cannabinoids and their metabolites in different matrices by 
modern analytical techniques - a review. Analytica chimica acta. 2015;874:11-25. 
53. Health MSDo. Adverse Events Associated with the Use of Synthetic 
Cannabinoids—Mississippi, 2015. Mississippi Morbidity Report. 2015;31(4):1-5. 
54. Lisi DM. Designer drugs. Patients may be using synthetic cannabinoids more than 
you think. JEMS : a journal of emergency medical services. 2014;39(9):56-9. 
55. EMCDDA. European Drug Report: Trends and Developments 2016. 2016. 
56. EMCDDA. EU Drug Markets Report: In-depth Analysis. 2016. 
57. EMCDDA. European Drug Report 2015: Trends and Developments. 2015. 
58. Bosier B, Muccioli GG, Hermans E, Lambert DM. Functionally selective 
cannabinoid receptor signalling: therapeutic implications and opportunities. Biochemical 
pharmacology. 2010;80(1):1-12. 
59. Guzman M, Sanchez C, Galve-Roperh I. Cannabinoids and cell fate. 
Pharmacology & therapeutics. 2002;95(2):175-84. 
60. Raymon LP, Walls H. C. . Pharmacology of Cannabinoids. In: Mahmoud A. 
ElSohly P, editor. Marijuana and the Cannabinoids. Totowa, New Jersey: Humana Press 
Inc.; 2007. p. 97-123. 
61. Howlett AC. Cannabinoid receptor signaling. Handbook of experimental 
pharmacology. 2005(168):53-79. 
References 
- 54 - 
 
62. Velasco G, Galve-Roperh I, Sanchez C, Blazquez C, Haro A, Guzman M. 
Cannabinoids and ceramide: two lipids acting hand-by-hand. Life sciences. 
2005;77(14):1723-31. 
63. Derkinderen P, Toutant M, Burgaya F, Le Bert M, Siciliano JC, de Franciscis V, et 
al. Regulation of a neuronal form of focal adhesion kinase by anandamide. Science. 
1996;273(5282):1719-22. 
64. Wartmann M, Campbell D, Subramanian A, Burstein SH, Davis RJ. The MAP 
kinase signal transduction pathway is activated by the endogenous cannabinoid 
anandamide. FEBS letters. 1995;359(2-3):133-6. 
65. De Petrocellis L, Melck D, Palmisano A, Bisogno T, Laezza C, Bifulco M, et al. The 
endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. 
Proceedings of the National Academy of Sciences of the United States of America. 
1998;95(14):8375-80. 
66. Henriet P, Gaide Chevronnay HP, Marbaix E. The endocrine and paracrine control 
of menstruation. Molecular and cellular endocrinology. 2012;358(2):197-207. 
67. Su RW, Fazleabas AT. Implantation and Establishment of Pregnancy in Human 
and Nonhuman Primates. Advances in anatomy, embryology, and cell biology. 
2015;216:189-213. 
68. Markee JE. Menstruation in intraocular endometrial transplants in the Rhesus 
monkey. American journal of obstetrics and gynecology. 1978;131(5):558-9. 
69. Cha J, Sun X, Dey SK. Mechanisms of implantation: strategies for successful 
pregnancy. Nature medicine. 2012;18(12):1754-67. 
70. Burton GJ, Jauniaux E. What is the placenta? American journal of obstetrics and 
gynecology. 2015;213(4 Suppl):S6 e1, S6-8. 
71. Salamonsen LA, Nie G, Hannan NJ, Dimitriadis E. Society for Reproductive 
Biology Founders' Lecture 2009. Preparing fertile soil: the importance of endometrial 
receptivity. Reproduction, fertility, and development. 2009;21(7):923-34. 
72. Gude NM, Roberts CT, Kalionis B, King RG. Growth and function of the normal 
human placenta. Thrombosis research. 2004;114(5-6):397-407. 
73. James JLaC, L. W. Structure and Development of the Human Placenta. In: Parolini 
O, editor.: Taylor & Francis Group; 2015. 
74. Dunn CL, Kelly RW, Critchley HO. Decidualization of the human endometrial 
stromal cell: an enigmatic transformation. Reproductive biomedicine online. 
2003;7(2):151-61. 
75. Anacker J, Segerer SE, Hagemann C, Feix S, Kapp M, Bausch R, et al. Human 
decidua and invasive trophoblasts are rich sources of nearly all human matrix 
metalloproteinases. Molecular human reproduction. 2011;17(10):637-52. 
76. Fonseca BM, Correia-da-Silva G, Almada M, Costa MA, Teixeira NA. The 
Endocannabinoid System in the Postimplantation Period: A Role during Decidualization 
and Placentation. International journal of endocrinology. 2013;2013:510540. 
77. Jackson P, Barrowclough IW, France JT, Phillips LI. A successful pregnancy 
following total hysterectomy. British journal of obstetrics and gynaecology. 
1980;87(5):353-5. 
78. Martin JN, Jr., Sessums JK, Martin RW, Pryor JA, Morrison JC. Abdominal 
pregnancy: current concepts of management. Obstetrics and gynecology. 1988;71(4):549-
57. 
79. Maccarrone M. Endocannabinoids: friends and foes of reproduction. Progress in 
lipid research. 2009;48(6):344-54. 
80. Di Blasio AM, Vignali M, Gentilini D. The endocannabinoid pathway and the female 
reproductive organs. Journal of molecular endocrinology. 2013;50(1):R1-9. 
81. Wang H, Xie H, Sun X, Kingsley PJ, Marnett LJ, Cravatt BF, et al. Differential 
regulation of endocannabinoid synthesis and degradation in the uterus during embryo 
implantation. Prostaglandins & other lipid mediators. 2007;83(1-2):62-74. 
References 
- 55 - 
 
82. El-Talatini MR, Taylor AH, Elson JC, Brown L, Davidson AC, Konje JC. 
Localisation and function of the endocannabinoid system in the human ovary. PloS one. 
2009;4(2):e4579. 
83. Nir I, Ayalon D, Tsafriri A, Cordova T, Lindner HR. Letter: Suppression of the cyclic 
surge of luteinizing hormone secretion and of ovulation in the rat by delta 1-
tetrahydrocannabinol. Nature. 1973;243(5408):470-1. 
84. Schuel H, Burkman LJ, Lippes J, Crickard K, Forester E, Piomelli D, et al. N-
Acylethanolamines in human reproductive fluids. Chemistry and physics of lipids. 
2002;121(1-2):211-27. 
85. Wang H, Xie H, Guo Y, Zhang H, Takahashi T, Kingsley PJ, et al. Fatty acid amide 
hydrolase deficiency limits early pregnancy events. The Journal of clinical investigation. 
2006;116(8):2122-31. 
86. Paria BC, Song H, Wang X, Schmid PC, Krebsbach RJ, Schmid HH, et al. 
Dysregulated cannabinoid signaling disrupts uterine receptivity for embryo implantation. 
The Journal of biological chemistry. 2001;276(23):20523-8. 
87. Wang H, Dey SK, Maccarrone M. Jekyll and hyde: two faces of cannabinoid 
signaling in male and female fertility. Endocrine reviews. 2006;27(5):427-48. 
88. Das SK, Paria BC, Chakraborty I, Dey SK. Cannabinoid ligand-receptor signaling 
in the mouse uterus. Proceedings of the National Academy of Sciences of the United 
States of America. 1995;92(10):4332-6. 
89. Schmid PC, Paria BC, Krebsbach RJ, Schmid HH, Dey SK. Changes in 
anandamide levels in mouse uterus are associated with uterine receptivity for embryo 
implantation. Proceedings of the National Academy of Sciences of the United States of 
America. 1997;94(8):4188-92. 
90. Schou J, Prockop LD, Dahlstrom G, Rohde C. Penetration of delta-9-
tetrahydrocannabinol and 11-OH-delta-9-tetrahydrocannabinol through the blood-brain 
barrier. Acta pharmacologica et toxicologica. 1977;41(1):33-8. 
91. Bar-Oz B, Klein J, Karaskov T, Koren G. Comparison of meconium and neonatal 
hair analysis for detection of gestational exposure to drugs of abuse. Archives of disease 
in childhood Fetal and neonatal edition. 2003;88(2):F98-F100. 
92. Harbison RD, Mantilla-Plata B, Lubin DJ. Alteration of delta 9-
tetrahydrocannabinol-induced teratogenicity by stimulation and inhibition of its 
metabolism. The Journal of pharmacology and experimental therapeutics. 
1977;202(2):455-65. 
93. Fried PA, Watkinson B, Willan A. Marijuana use during pregnancy and decreased 
length of gestation. American journal of obstetrics and gynecology. 1984;150(1):23-7. 
94. Gibson GT, Baghurst PA, Colley DP. Maternal alcohol, tobacco and cannabis 
consumption and the outcome of pregnancy. The Australian & New Zealand journal of 
obstetrics & gynaecology. 1983;23(1):15-9. 
95. Zuckerman B, Frank DA, Hingson R, Amaro H, Levenson SM, Kayne H, et al. 
Effects of maternal marijuana and cocaine use on fetal growth. The New England journal 
of medicine. 1989;320(12):762-8. 
96. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. 
Lancet. 2009;374(9698):1383-91. 
97. Tennes K, Avitable N, Blackard C, Boyles C, Hassoun B, Holmes L, et al. 
Marijuana: prenatal and postnatal exposure in the human. NIDA research monograph. 
1985;59:48-60. 
98. Fried PA, Watkinson B, Grant A, Knights RM. Changing patterns of soft drug use 
prior to and during pregnancy: a prospective study. Drug and alcohol dependence. 
1980;6(5):323-43. 
99. Sherwood RA, Keating J, Kavvadia V, Greenough A, Peters TJ. Substance misuse 
in early pregnancy and relationship to fetal outcome. European journal of pediatrics. 
1999;158(6):488-92. 
References 
- 56 - 
 
100. Jutras-Aswad D, DiNieri JA, Harkany T, Hurd YL. Neurobiological consequences 
of maternal cannabis on human fetal development and its neuropsychiatric outcome. 
European archives of psychiatry and clinical neuroscience. 2009;259(7):395-412. 
101. Hatch EE, Bracken MB. Effect of marijuana use in pregnancy on fetal growth. 
American journal of epidemiology. 1986;124(6):986-93. 
102. El Marroun H, Tiemeier H, Steegers EA, Jaddoe VW, Hofman A, Verhulst FC, et 
al. Intrauterine cannabis exposure affects fetal growth trajectories: the Generation R 
Study. Journal of the American Academy of Child and Adolescent Psychiatry. 
2009;48(12):1173-81. 
103. Hofman A, Jaddoe VW, Mackenbach JP, Moll HA, Snijders RF, Steegers EA, et al. 
Growth, development and health from early fetal life until young adulthood: the Generation 
R Study. Paediatric and perinatal epidemiology. 2004;18(1):61-72. 
104. Gunn JK, Rosales CB, Center KE, Nunez AV, Gibson SJ, Ehiri JE. The effects of 
prenatal cannabis exposure on fetal development and pregnancy outcomes: a protocol. 
BMJ open. 2015;5(3):e007227. 
105. El Marroun H, Tiemeier H, Steegers EA, Roos-Hesselink JW, Jaddoe VW, Hofman 
A, et al. A prospective study on intrauterine cannabis exposure and fetal blood flow. Early 
human development. 2010;86(4):231-6. 
106. Saurel-Cubizolles MJ, Prunet C, Blondel B. Cannabis use during pregnancy in 
France in 2010. BJOG : an international journal of obstetrics and gynaecology. 
2014;121(8):971-7. 
107. Blackard C, Tennes K. Human placental transfer of cannabinoids. The New 
England journal of medicine. 1984;311(12):797. 
108. Hutchings DE, Martin BR, Gamagaris Z, Miller N, Fico T. Plasma concentrations of 
delta-9-tetrahydrocannabinol in dams and fetuses following acute or multiple prenatal 
dosing in rats. Life sciences. 1989;44(11):697-701. 
109. Martin BR, Dewey WL, Harris LS, Beckner JS. 3H-delta9-tetrahydrocannabinol 
distribution in pregnant dogs and their fetuses. Research communications in chemical 
pathology and pharmacology. 1977;17(3):457-70. 
110. Abrams RM, Cook CE, Davis KH, Niederreither K, Jaeger MJ, Szeto HH. Plasma 
delta-9-tetrahydrocannabinol in pregnant sheep and fetus after inhalation of smoke from a 
marijuana cigarette. Alcohol and drug research. 1985;6(5):361-9. 
111. Boskovic R, Klein J, Woodland C, Karaskov T, Koren G. The role of the placenta in 
variability of fetal exposure to cocaine and cannabinoids: a twin study. Canadian journal of 
physiology and pharmacology. 2001;79(11):942-5. 
112. Khare M, Taylor AH, Konje JC, Bell SC. Delta9-tetrahydrocannabinol inhibits 
cytotrophoblast cell proliferation and modulates gene transcription. Molecular human 
reproduction. 2006;12(5):321-33. 
113. Costa MA, Fonseca BM, Marques F, Teixeira NA, Correia-da-Silva G. The 
psychoactive compound of Cannabis sativa, Delta-tetrahydrocannabinol (THC) inhibits the 
human trophoblast cell turnover. Toxicology. 2015;334:94-103. 
114. Cabán B. SLA, Huffman C. A., Whitecar P. W., Haley C. Synthetic Cannabinoid 
and Synthetic Cocaine Use during Pregnancy in a Soldier. J Subst Abuse Alcohol. 
2013;1(1):1002. 
115. Brents LK. Marijuana, the Endocannabinoid System and the Female Reproductive 
System. The Yale journal of biology and medicine. 2016;89(2):175-91. 
116. Tomiyama K, Funada M. Cytotoxicity of synthetic cannabinoids on primary 
neuronal cells of the forebrain: the involvement of cannabinoid CB1 receptors and 
apoptotic cell death. Toxicology and applied pharmacology. 2014;274(1):17-23. 
117. Couceiro J, Bandarra S, Sultan H, Bell S, Constantino S, Quintas A. Toxicological 
impact of JWH-018 and its phase I metabolite N-(3-hydroxypentyl) on human cell lines. 
Forensic science international. 2016;264:100-5. 
References 
- 57 - 
 
118. Aguirre-Rueda D, Guerra-Ojeda S, Aldasoro M, Iradi A, Obrador E, Mauricio MD, 
et al. WIN 55,212-2, agonist of cannabinoid receptors, prevents amyloid beta1-42 effects 
on astrocytes in primary culture. PloS one. 2015;10(4):e0122843. 
119. Benard G, Massa F, Puente N, Lourenco J, Bellocchio L, Soria-Gomez E, et al. 
Mitochondrial CB(1) receptors regulate neuronal energy metabolism. Nature 
neuroscience. 2012;15(4):558-64. 
120. Mackie K, Stella N. Cannabinoid receptors and endocannabinoids: evidence for 
new players. The AAPS journal. 2006;8(2):E298-306. 
121. Fonseca BM, Correia-da-Silva, G., Almada, M., Costa, M. A., Ferreira, R., Teixeira 
N. A. Characterization of the endocannabinoid system in telomerase-immortalized human 
endometrial stromal cell line, St-T1b. FEBS Journal. 2013;280(s1):3-617. 
122. Fisar Z, Singh N, Hroudova J. Cannabinoid-induced changes in respiration of brain 
mitochondria. Toxicology letters. 2014;231(1):62-71. 
123. Wiley JL, Marusich JA, Huffman JW. Moving around the molecule: relationship 
between chemical structure and in vivo activity of synthetic cannabinoids. Life sciences. 
2014;97(1):55-63. 
124. Moghadam KK, Kessler CA, Schroeder JK, Buckley AR, Brar AK, Handwerger S. 
Cannabinoid receptor I activation markedly inhibits human decidualization. Molecular and 
cellular endocrinology. 2005;229(1-2):65-74. 
125. Giuliano M, Pellerito O, Portanova P, Calvaruso G, Santulli A, De Blasio A, et al. 
Apoptosis induced in HepG2 cells by the synthetic cannabinoid WIN: involvement of the 
transcription factor PPARgamma. Biochimie. 2009;91(4):457-65. 
126. Hong Y, Zhou Y, Wang Y, Xiao S, Liao DJ, Zhao Q. PPARγ mediates the effects of 
WIN55,212-2, an synthetic cannabinoid, on the proliferation and apoptosis of the BEL-
7402 hepatocarcinoma cells. Molecular Biology Reports. 2013;40(11):6287-93. 
127. Salamonsen LA, Zhang J, Hampton A, Lathbury L. Regulation of matrix 
metalloproteinases in human endometrium. Hum Reprod. 2000;15 Suppl 3:112-9. 
128. Mitchell MD, Sato TA, Wang A, Keelan JA, Ponnampalam AP, Glass M. 
Cannabinoids stimulate prostaglandin production by human gestational tissues through a 
tissue- and CB1-receptor-specific mechanism. American journal of physiology 
Endocrinology and metabolism. 2008;294(2):E352-6. 
129. Rechtman MP, Zhang J, Salamonsen LA. Effect of inhibition of matrix 
metalloproteinases on endometrial decidualization and implantation in mated rats. Journal 
of reproduction and fertility. 1999;117(1):169-77. 
130. Blazquez C, Salazar M, Carracedo A, Lorente M, Egia A, Gonzalez-Feria L, et al. 
Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 
expression. Cancer research. 2008;68(6):1945-52. 
131. Preet A, Qamri Z, Nasser MW, Prasad A, Shilo K, Zou X, et al. Cannabinoid 
receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer 
growth and metastasis. Cancer prevention research (Philadelphia, Pa). 2011;4(1):65-75. 
132. Milne SA, Perchick GB, Boddy SC, Jabbour HN. Expression, localization, and 
signaling of PGE(2) and EP2/EP4 receptors in human nonpregnant endometrium across 
the menstrual cycle. The Journal of clinical endocrinology and metabolism. 
2001;86(9):4453-9. 
133. Mestre L, Correa F, Docagne F, Clemente D, Guaza C. The synthetic cannabinoid 
WIN 55,212-2 increases COX-2 expression and PGE2 release in murine brain-derived 
endothelial cells following Theiler's virus infection. Biochemical pharmacology. 
2006;72(7):869-80. 
 
